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REGULATION OF OSTEOCLAST DIFFERENTIATION AND ACTIVATION  
IN RESPONSE TO ENVIRONMENTAL STIMULI 
 
HAOMING LIU  
 
ABSTRACT 
 Bone is a biomaterial composed of organic and inorganic molecules that are 
continuously remodeled to preserve structural integrity and allow adaptation to stress. Two 
major types of cells are responsible for this process: the osteoblast that synthesizes the bone 
and the osteoclast that resorbs the bone. A delicate balance between the function of these 
two cell types is required to maintain proper bone health and body homeostasis.  
 Three independent projects were conducted to investigate the functions of 
osteoclasts in response to manipulations of their environment. The differentiation and 
activation of osteoclasts depends largely on cell-cell communication and integration of 
signals such as stress and metabolic status. The canonical pathway of osteoclast 
differentiation is driven by receptor activator of NFKB ligand (RANKL), a cytokine 
produced in large part by cells of the osteoblast lineage. In inflammatory states, RANKL 
is also made by T cells and synovial cells in the joint. In addition to altering RANKL, 
inflammation may enhance osteoclast formation through various other cytokines. In project 
one, we examined the effect of inflammatory cytokine interleukin (IL)-X in a mouse 
inflammatory arthritis model and found that it is not required for osteoclast activity. 
  vi 
Previous studies have reported that other inflammatory cytokines, including as TNF and 
IL-6 are able to induce osteoclast differentiation in mice, in addition to the RANKL 
pathway. Project two investigates whether these cytokines could have the same function in 
humans. In addition to inflammatory cytokines, osteoclasts have been shown to respond to 
extracellular stimuli such as stress and metabolic status. Factors responsible for integrating 
these signals, TSC2 and the mTORC1 complex, were investigated for  their role in 
osteoclast activity, regulation of communication between osteoclasts and osteoblasts, and 
subsequent formation of a high bone mass phenotype.  
 All three projects have clinical correlations in human. Studying the effects of 
inflammatory cytokines could reveal mechanisms and strategies for prevention of erosions 
in rheumatoid arthritis and other inflammatory arthritidies. Heterozygous mice for the Tsc2 
gene can be used as a mouse model for diseases including tuberous sclerosis complex and 
Paget’s disease. Moreover, understanding the role of mTORC1 complex activity in 
regulating bone mass could shed light on the potential effect of long-term rapamycin 
treatment for patients. As demonstrated through these projects, bone is highly dynamic and 
regulated by numerous physiological processes.  
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INTRODUCTION 
Overview 
 Bone is a composite tissue composed of protein and mineral. The three main cell 
types residing in bone are osteoclasts (OC), which degrade bone, osteoblasts (OB) that 
create new bone, and osteocytes, specialized cells of the osteoblast lineage that act as 
mechanosensors. Bone is a highly dynamic tissue, in which degradation and deposition of 
new bone are continuously active, leading to a complete turnover of the skeleton occurring 
every 10 years. Bone remodeling is necessary for growth, damage repair (for example after 
a fracture), and the regulation of calcium-phosphate metabolism. The remodeling process 
is executed by the concerted and sequential effort of OC and OB, spatially linked in what 
is called the bone remodeling unit1. 
 OC are multinucleated giant cells that differentiate from myeloid osteoclast 
precursors (OCP) under the influence of the cytokines: macrophage colony stimulating 
factor (M-CSF) and receptor activator of NF-κB (RANK) ligand (RANKL)2. M-CSF is 
a cytokine released by OBs and stromal cells, and binds to its receptor, c-Fms, on early 
OCP. This binding activates subsequent signaling pathways that promote the survival 
and differentiation of these OCPs3. RANKL on OBs also binds to its receptor RANK 
on the expanded precursor cells, and stimulates them to commit to the OC phenotype4. 
Osteoprotegerin (OPG) inhibits this osteoclastogenesis pathway by competing with 
RANK for RANKL binding5. Animals that lack OPG develop osteoporosis because of 
accelerated OC generation4. OCs degrade the bone by secreting proteolytic enzymes - 
cathepsin A, B, K - and acid (H+), which hydrolyze and solubilize the organic and 
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inorganic components of the bone. Enzyme and proton secretion is directed into the 
resorption lacunae which is isolated from the rest of the bone microenvironment by the 
osteoclasts themselves, forming a spatial barrier1.  
 After the resorption phase performed by osteoclasts, mesenchymal stem cells are 
recruited to the site of resorption and subsequently differentiate into OBs6. Mechanisms of 
mesenchymal stem cell recruitment are not yet fully understood, however evidence has 
shown that osteoclast-derived coupling factors such as collagen triple helix repeat 
containing 1 (CTHRC1) is able to communicate to OB6. As the committed pre-OC matures 
into a multinucleated OC, complement component 3a (C3a) is derived from these 
  
Figure 1. Schematic model of the RANK-dependent pathway of osteoclastogenesis and 
osteoclastic bone resorption. Osteoblasts express RANKL and stromal cells secrete M-CSF, both of 
which bind to their receptors on osteoclast precursor cells with monocyte/macrophage lineage. 
This binding leads to commitment of the cells to osteoclast differentiation, and can be inhibited 
by OPG and stimulated by parathyroid hormone (PTH). The differentiated osteoclast forms a 
ruffled membrane and attaches to the bone via avβ3 integrin. Electrogenic proton pumps then 
acidifies the local extracellular milieu at the site of attachment, and HCO3-/Cl- exchanger 
maintains intracellular pH. The acidic microenvironment degrades mineral structures and organic 
matrix of the bone, and leads to bone resorption4. 
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multinucleated OC and acts on bone marrow stromal cells (BMSC) to stimulate 
osteoblastogenesis. CTHRC1 is secreted from mature active OC during bone resorption 
and stimulates OB differentiation as well as recruitment of BMSC or mesenchymal stem 
cells (MSC) to resorption lacunae6. After acquiring a fully mature phenotype, OBs secrete 
osteoid, the organic component of bone that will be later mineralized by the incorporation 
of hydroxyapatite7. Some OBs become incorporated within the matrix and subsequently 
become osteocytes, which do not produce bone matrix and function mainly to monitor bone 
quality and coordinate remodeling through the expression of specific membrane ligands 
and through the secretion of specific factors1,8.   
 In this thesis, three manipulations of OC environmental stimuli were made to 
examine the regulation of OC differentiation and activation, and how its interaction with 
OB can impact the formation of bone phenotypes related to diseases such as rheumatoid 
arthritis, tuberous sclerosis complex, and Paget’s disease.  
1.1. The inflammatory cytokine IL-X in a mouse model of inflammatory arthritis  
1.1.1 Project background  
 Interleukin-34 (IL-X) is a cytokine induced by tumor necrosis factor (TNF) and 
interleukin-1B (IL-1β), two inflammatory cytokines that are highly expressed in diseases 
such as rheumatoid arthritis (RA)9. IL-X is thought to have mostly local actions, as it is not 
detected in the circulation10,11. IL-X has been demonstrated to bind to two receptors: the 
IL-X receptor (IL-XR) and colony stimulating factor 1 receptor (CSF-1R)12. Signaling 
through CSF-1R is essential for myeloid cell proliferation and survival, including for the 
differentiation of osteoclasts. Mice deficient in CSF-1R are osteopetrotic and completely 
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lack osteoclasts13. The primary ligand for CSF-1R is M-CSF, which is essential for OC 
differentiation under normal physiologic conditions3. However, mice deficient in M-CSF 
(op/op mice) develop osteoclasts with age, suggesting the presence of other ligands for 
CSF-1R14.  
 The discovery that IL-X is also a ligand for CSF-1R suggested that once expressed, 
IL-X could play a role in OC differentiation. Supporting this hypothesis, IL-X is highly 
expressed in op/op mice, coincident with the appearance of OCs15. Studies have shown that 
IL-X stimulates the adhesion and differentiation of OC precursor cells in the presence of 
RANKL16. It has further been demonstrated that IL-X can substitute for M-CSF in in vitro 
OC differentiation from murine bone marrow myeloid cells and human CD14+ cells9,16 and 
injection of IL-X into the bone microenvironment promotes bone loss17. Although IL-X 
does not appear to play a role in basal osteoclast differentiation and bone remodeling, it is 
possible that IL-X plays an important role in OC differentiation under inflammatory 
conditions (V. Chitu, R. Stanley, personal communication, September 2016).  In response 
to inflammation, TNF-α and IL-1β stimulate fibroblast-like synovial cells (FLS) to express 
IL-X11.  
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1.1.2 K/BxN serum transfer arthritis (STA) as a model for human inflammatory arthritis  
 First reported by the Mathis/Benoist laboratory in 1996, the K/BxN serum-transfer 
arthritis (STA) is a frequently used mouse model of inflammatory arthritis18. It was 
discovered by crossing T-cell receptor (TCR) transgenic KRN mice on a specific C57BL/6 
background with autoimmune-prone non-obese diabetic (NOD) mice. The F1-generation 
K/BxN mice develop severe arthritis by the age of 4–5 weeks19. In the adaptive immune 
system, antigen presenting cells (APCs) that express MHC-II molecules are able to bind to 
TCRs on T cells and initiate subsequent immune response20. In K/BxN mice, there is a 
NOD-derived MHCII,  I-Ag7, on APCs which binds to and activates T cells that express 
the transgenic KRN TCR, leading to B cell activation and production of immunoglobulins 
(IgGs)19. The I-Ag7 molecule in K/BxN mice presents a ubiquitously expressed self-
antigen, glucose-6-phosphate isomerase (G6PI), an enzyme responsible for the 
interconversion between d-glucose-6-phosphate and d-fructose-6-phosphate21,22. This 
leads to the production of B cells producing antibodies against G6PI which causes 
inflammatory arthritis by mechanisms that remain unclear. Administering serum from 
these K/BxN mice, that contains disease-inducing IgGs, induces an inflammatory arthritis 
referred to as serum transfer arthritis (STA). STA is used as a model for autoimmune 
arthritis, such as rheumatoid arthritis (RA)23. Transfer of serum from arthritic K/BxN mice 
leads to reproducible arthritis with rapid onset in mice from many other strains21. The 
various strains that can develop disease after serum transfer include BALB/c, C57BL/6, 
and DBA/1 mice24. The pathogenesis of STA involves a range of immune mediators 
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including cytokines and factors involved in pain and bone erosion, making STA and 
excellent mouse model for studying effector mechanisms in inflammatory arthritis21.   
1.1.3 Aims and hypothesis 
  The proximity of IL-X producing FLS cells to bone erosions in the joint, and the 
properties of IL-X discussed above, lead to the hypothesis that IL-X plays a supporting role 
in the erosions by inflammatory arthritis. We would expect to see that in the absence of IL-
X there would be less OC activity and bone erosion in mouse with inflammatory arthritis.  
  
 
 
Figure 2. Schematic of the mechanism of action of K/BxN serum transfer arthritis model (STA). K/BxN 
mice are generated by crossing KRN T cell receptor transgenic (Tg) mice with non-obese diabetes (NOD) 
mice that are prone to develop diabetes. The onset and progression of arthritis in K/BxN mice are 
monitored by measuring thickness of the paw. Swelling in the paws indicate inflammation and presence 
of immunoglobulin against the self-antigen glucose-6-phosphate isomerase (G6PI, or GPI). The serum 
from animals with the disease can then be transferred to other strains including B6, Balb/c, and C3H.   
 7 
 
1.2. Human osteoclasts in rheumatoid arthritis  
1.2.1 Evidence supporting the existence of RANKL-independent osteoclastogenesis  
 Rheumatoid arthritis (RA) is an inflammatory disease that targets bones and 
causes bone erosions. Manifestations of RA include systemic bone loss and 
periarticular osteopenia, which is mainly due to the local release of inflammatory 
molecules25. In 2005, it was estimated that 1.5 million (0.6%) of US adults had RA, and 
this number was indicated to be on the rise26. Bone erosions in RA lead to structural 
damage to joints, and are mediated by osteoclasts, which are the principal cells for 
bone erosion and resorption27. A better understanding of the mechanisms for OC 
differentiation and activation will help define effective clinical approaches to inhibit 
bone erosions, and therefore treat patients with RA.  
 Although M-CSF/RANK pathway plays a vital role in physiological and 
pathological bone destruction, there is also evidence for RANK-independent 
osteoclastogenesis pathways28. It was found that mice with post-natal deletion of RANK 
still develop joint erosions in the setting of inflammatory arthritis. Cytokines in chronic 
inflammation, such as tumor necrosis factors (TNF) and interleukins (IL), are 
osteoclastogenic and promote severe local bone loss29. TNF is a 17-kDa cell signaling 
protein involved in systemic inflammation. It is produced primarily by monocytes, 
although it can also be produced by other cell types such as neutrophils, mast cells, and 
eosinophils30,31. TNF is one of the initial cytokines released in the acute phase of the 
immune reaction cascade in response to trauma or infection31. TNF and IL-1ß, another 
cytokine in the acute phase response, stimulate further production of other proteins 
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including the pro-inflammatory cytokines IL-6 and IL-8. TNF is able to induce fever and 
apoptotic cell death to inhibit viral replication31,32.  Dysregulation of TNF production has 
been implicated in a variety of human diseases including Alzheimer's disease33, major 
depression34, and psoriasis35. In contrast with the pro-inflammatory nature of TNF, IL-6 is 
an interleukin that acts as both a pro-inflammatory cytokine and an anti-inflammatory 
myokine – peptides that are derived from myocytes in response to muscular 
contractions31,36. IL-6 secreted by T cells and macrophages to stimulate immune response 
to inflammation is an important mediator of fever. It is able to cross the blood-brain barrier 
and initiate the production of prostaglandin E2 (PGE2) in the hypothalamus, thereby 
changing the body's temperature set point37. IL-6 has also been shown to be required for 
resistance against bacterium Streptococcus pneumoniae in mice38. In addition, OBs secrete 
IL-6 to stimulate OC formation39.  
 Both TNF and IL-6 cytokines are elevated in RA, and a recent report suggests 
that they can synergistically stimulate the differentiation of OC precursors, suggesting 
that alternative pathways of OC formation and erosion may play a role in the setting 
of inflammatory arthritis. Mouse osteoclast-like cells differentiate in response to TNF 
and IL-6 in vitro, as indicated by TNF/IL-6–induced OC formation from RANK-/- 
synovial cultures. In this recent report, the presence of RANK-independent 
osteoclastogenesis pathway in vivo was observed using the K/BxN inflammatory 
arthritis model, where both TNF and IL-6 were highly up-regulated. It was found that 
even in the absence of RANK, the mice still developed bone lesions and TRAP-
positive osteoclasts in inflamed joints, indicating that RANK-independent 
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OCformation can occur in inflammatory conditions in vivo40.  
 It has also been confirmed that the osteoclastogenesis pathway by TNF and IL-
6 is RANK-independent, because the OC activities were not inhibited by OPG. In 
terms of the downstream mechanism, it was proposed that TNF and IL-6 induce the 
expression of the c-Fos gene, which is essential for the transcription of Nfatc1, the 
critical transcription factor for OCdifferentiation3.  These RANK-independent 
osteoclastogenesis pathways imply that cytokine blockade, with either TNFα blockers 
or IL-6 receptor blockers, could have additional effects on inhibiting OC formation 
and alleviating bone erosions in inflammatory joint diseases.  
 
Figure 3. Schematic model of the differentiation of osteoclast-like cells induced by TNFα and IL-6. 
IL-6 binds to its receptor IL-6α on osteoclast-like cells and induces the signaling cascade that 
upregulates c-Fos expression at the protein level. At the same time, TNFα binds to TNFR and 
activates TRAFs to stimulate the activities of both c-Fos and NF-κB, leading to the expression of NF-
ATc1 and subsequent OCactivities. This induction is dependent on JAK pathway and the MEK/ERK 
pathway is likely to be involved. TNFR= TNF receptor; TRAFs= TNF receptor associated factors; 
NFATc1=Nuclear factor of activated T-cells cytoplasmic 13. 
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1.2.2 Aims and hypothesis 
 The immediate goal of this project is to determine conditions for RANK-
independent, TNF/IL6 driven OC differentiation. The ultimate goal of this project would 
be to examine whether the alternative pathway is enhanced in RA patients and whether it 
varies with disease activity. The hypothesis is that RA patients will be more sensitive to 
TNF/IL-6 driven osteoclastogenesis than healthy controls. If RANK-independent 
osteoclastogenesis is enhanced in RA patients, then it would imply that blocking either 
TNF or IL-6 actions could have the additional effect of inhibiting OC formation and 
alleviating joint destruction. We are in the process of developing an assay to test TNF/IL-
6 stimulated OC differentiation and resorptive function from frozen human PBMC. The 
optimal conditions for TNF/IL-6–induced OC cultures will be determined, so that the 
presence of human osteoclasts derived from PBMC independently of RANKL can be 
confirmed. The precursors of these osteoclasts will also be identified to examine whether 
TNF/IL6-induced osteoclasts derive from the same circulating precursor as RANKL-
induced osteoclasts. 
 The first step to approach the ultimate goal of learning about human OC activation 
via alternative pathway would be to develop an assay for TNF/IL-6 driven OC 
differentiation from frozen human peripheral blood mononuclear (PBMC) samples. We 
expect to find a condition in which osteoclasts will form in TNF/IL-6 cultures, though less 
efficiently than in RANKL cultures, while neither TNF nor IL-6 alone will induce OC 
formation. Next, we would test whether TNF/IL-6 are sufficient to induce 
osteoclastogenesis from human PBMC. The reason behind this step is that the production 
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of OC in the presence of TNF/IL-6 could be due to their indirect induction of RANKL, 
which leads to the classic pathway. To understand more about the mechanism, we would 
then test if the OC precursor population that responds to TNF/IL-6 is identical to that 
responding to RANKL. We are curious to find out about the cluster of differentiation (CD) 
markers present on the cells that respond to either pathways.   
1.3. Absence of metabolic stimulation:  Osteoclast-specific Tsc2 deletion in mice 
causes a high bone mass, with clinical implications for bone lesions in Tuberous 
Sclerosis Complex 
1.3.1 Overview of the disease – Tuberous Sclerosis Complex (TSC)  
 Tuberous sclerosis or Tuberous Sclerosis Complex is an autosomal dominant 
disorder that affects multiple body systems with high penetrance and variable expression, 
and can cause benign and less commonly malignant lesions41. Neurological manifestations 
are the most frequent morbidities in patients with TSC. Epilepsy is the most common 
symptom, affecting 8 out of 10 patients and frequently represents the first sign of the 
disease42. Lymphangioleiomyomatosis (LAM) is the most frequent pulmonary 
manifestation of TSC, found in at least 40% of women with TSC and can be diagnosed 
based on chest computed tomography (CT) scan findings43. Sclerotic bone lesions – local 
increase of bone density – are described in several reviews regarding the radiological 
aspects of TSC and are considered as abnormalities without definite clinical significance44. 
After renal angiomyolipomas (AMLs) and cortical tubers, sclerotic bone lesions are the 
third most common finding on imaging in TSC patients being detected by CT45. 
Radiographic appearance of sclerotic bone lesions is commonly associated with patchy 
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areas of increased bone density. The sacrum and proximal femur can also be involved, 
together with the classic vertebral and iliac involvement46. 
 The genotype-phenotype correlation in Tuberous Sclerosis has been analyzed 
extensively. The probable link between TSC and a gene on chromosome 9q34 was first 
described in 1994. This gene was called TSC1 but linkage with this region of the genome 
was not found for all affected families47. Therefore, it was theorized that there be at least 
one other locus associated with the disease - the locus 16p13 was then linked to Tuberous 
Sclerosis and the gene involved was named TSC248. Individuals with Tuberous Sclerosis 
are heterozygous for TSC1 or TSC2. It is well recognized that in order to develop a lesion 
a second somatic mutation in the other copy of the gene must occur. Loss of heterozygosity 
is therefore necessary for the development of the phenotype49.  
1.2.2 The Role of mTORC1 Signaling in TSC 
 Rapamycin was discovered as a product of a strain of bacteria called Streptomyces 
Hygroscopicus isolated from a soil sample from an island called Rapa Nui (Easter Island)50. 
Rapamycin associates with FKB12 protein, and the resultant complex is identified to 
directly inhibit a single protein, which is recognized as mammalian Target of Rapamycin 
(mTOR)51. The mTOR protein assembles into two different complexes: mTORC1 and 
mTORC2. While mTORC1 is very sensitive to rapamycin, mTORC2 is insensitive to acute 
rapamycin treatment but sensitive after chronic exposure52. Less is known about the 
activity of mTORC2 compared to mTORC1, but mTORC2 appears to play a role in the 
regulation of the actin cytoskeleton53. 
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 The activity of mTORC1 is regulated through a protein complex formed by TSC1 
and TSC2. The loss of either protein stimulates mTOR dependent phosphorylation of its 
substrates54. A key readout of mTORC1 activity is phosphorylation of S6 Kinase (S6K), a 
70kD protein  involved in the control of mRNA translation55. Rapamycin decreases the 
activation of S6K through phosphorylation, and S6K was found to be highly 
phosphorylated in cells lacking the TSC1-TSC2 complex, suggesting that constitutive 
mTORC1 signaling might contribute to TSC pathology54. In TSC1 or TSC2 deficient cells, 
in which mTORC1 is constitutively hyperactive, mRNA translation is promoted due to the 
increased activity of S6K. The link between TSC1-TSC2 complex and mTOR was found 
to be a member of the RAS superfamily called Ras-homologue enriched in brain (RHEB)56. 
When the TSC1-TSC2 complex is active, TSC2 stimulates the conversion from the GTP-
bound state of RHEB (active) to the GDP-bound state (inactive). The inactive form of 
RHEB then binds to mTORC1 and consequently inhibits its activity57. Therefore, loss of 
TSC1-TSC2 triggers relieves mTORC1 inhibition, leading to aberrant mRNA translation 
and, through increased ribosomal biogenesis, total protein synthesis. Under normal 
conditions, mTORC1 can sense signals indicating the presence of nutrients, availability of 
ATP, hormones such as insulin, growth factors and cytokines, and therefore functions as a 
signal integration molecule that contributes to downstream cell growth and differentiation58. 
The activity of mTORC1 is also sensitive to amino acid availability through the RAG 
family of proteins59. The loss of TSC1-TSC2 complex results in an uncontrollable 
hyperactivation of mTORC1, regardless of the environmental status. A schematic of the 
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components of the pathway relevant to the pathway described above is presented in Figure 
4. 
 
Figure 4. Schematic of TSC inhibition of mTOR signaling activity via RHEB. TSC2 binds TSC1 to form the TSC 
protein complex, which integrates inputs from the cellular environment to inhibit mTORC1. The TSC protein 
acts as a GTPase-activating protein for Ras homology enriched in brain (RHEB), which directly stimulates 
mTORC1. TSC1-TSC2 complex is regulated in turn by many pathways and environmental stimuli, such as 
amino acids, nutrients, and stress. RAPTOR is a component of mTORC1 required for its activity60. 
 
1.2.3 Normal bone remodeling and the role of mTORC1 in bone formation  
 To address whether osteoclasts require Tsc2 or mTORC1 components for normal 
differentiation and function in vivo, previous experiment in the lab has utilized both 
induced and conditional deletion strategies to specifically target Tsc2 and Raptor in 
osteoclasts or their progenitors. Mx1-Cre; Raptorfl/fl mice were generated - Mx1 is 
expressed in myeloid precursors to encode a guanosine triphosphate (GTP)-metabolizing 
protein that participates in the cellular antiviral response61. Bone marrow cells harvested 
 15 
 
from Mx1-Cre; Raptor fl/fl mice were shown to have decreased OC formation when cultured 
in vitro with M-CSF and RANKL. Bone marrow cells were also harvested from Mx-1 Cre; 
Tsc2 fl/fl mice and cultured in same conditions. These experiments suggest that TSC2 and 
mTORC1 components are necessary for the differentiation of OCPs. 
 The differentiation of myeloid precursors into OC  not only leads to bone-resorbing 
activity, but is also hypothesized to stimulate bone formation through a process called OC-
OB coupling. Thus changes in bone formation rate could be due to changes in OB activity 
or due to alterations in OB activity secondary to indirect stimulation via OC. In normal 
conditions, the interaction between these two key cell types in bone is regulated and 
balanced. However, when coupling is impaired, the balance between the activity of OB 
and OC is lost and bone diseases could arise as a result: osteoporosis if resorption is higher 
than formation, and Paget-like bone diseases if the formation is increased more than the 
resorption1,2. Several potential OC-derived coupling factors, sometimes referred to as 
clastokines, have been identified using in vitro approaches. Among these, the factors with 
in vivo evidence of a role in this process are: collagen triple helix repeat containing 1 
(CTHRC1), complement factor 3a (C3a) and sphingosine-1-phosphate (S1P). Evidence 
indicates that global deficiency of Cthrc1 decreases OB number and bone formation in vivo. 
Moreover, Cthrc1 is found to be strongly induced in OCs active in resorption. Deletion of 
Cthrc1 in OC resulted in reduced bone mass without impairing bone functions, therefore 
suggesting a positive role of this factor in coupling6,39. The complement cascade 
component C3a is produced by OC cultures in vitro, and is observed to stimulate OB 
differentiation40. Sphingosine kinase 1 (SPHK1) and its product, S1P, are induced during 
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OC s differentiation and S1P promotes OB differentiation in vitro64. A better understanding 
of OC-OB coupling is likely to identify therapeutic targets for improving bone health and 
understanding the pathogenesis of bone diseases.  
Osteoporosis is a major public health problem, affecting over 9 million individuals 
in the US, with an additional 43 million having low bone density according to the 2004 
Report of the Surgeon General. While osteoporosis is a silent disease, the clinical 
consequence of fragility fracture is associated with significant morbidity and mortality 
risks and healthcare costs65. Although effective treatment is available, not all patients are 
willing to take or respond to existing therapies. Currently, less than a quarter of women 
with an osteoporotic fracture receive treatment and there is an unmet clinical need for 
alternative osteoporosis therapies66. Thus, understanding how key cell regulatory pathways 
like mTORC1 affect bone formation may lead to new strategies for treating osteoporosis. 
The increased activity of the mTOR pathway, responsible for the manifestations of 
TSC, has been widely explored in OB maturation and function but less is known about its 
effect in OC physiology. It has been suggested that rapamycin administration negatively 
impacted OCP formation, indicating a positive effect of mTORC1 in OC67. In vivo, micro-
CT evaluation demonstrated that rapamycin ameliorates age-related bone loss by 
decreasing the number of OC. In a mouse model of rheumatoid arthritis, inhibition of 
mTORC1 by rapamycin reduced synovial OC formation and thus, protected the animal 
against local bone erosions and cartilage loss68. Moreover, mTORC1 signaling was shown 
to be hyperactive in synovial membrane tissue samples of patients with rheumatoid arthritis, 
particularly in synovial OC53. This suggests that mTORC1 hyperactivity will lead to 
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increased OC formation and bone loss, and that targeted inhibitors of mTORC1 could be 
beneficial for bone health. 
1.2.4 Aims and hypothesis 
 We hypothesized that the sclerotic bone lesions seen in TSC patients could be 
modeled using the Tsc2+/- mouse model, but that restricted loss of TSC2 in OC would 
favor OC formation and result in low bone mass.  The first aim of the project was to 
examine skeletons of Tsc2+/- for sclerotic bone lesions using micro-computed tomography 
(micro-CT). The second aim of the project was to describe the bone phenotype in mice 
with deletion of Tsc2 gene specifically in bone marrow myeloid cells or OCPs. Mice were 
characterized for bone mass, bone mechanical properties, the age of onset of the phenotype, 
and difference between males and females.  
With more definite characterization of the bone phenotype, we would then examine the 
mechanism resulting in the observed bone phenotype.  
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METHODS 
2.1. The inflammatory cytokine IL-X in a mouse model of inflammatory arthritis 
2.1.1 Serum Transfer Arthritis Model 
 Experiments assessing the effect of IL-X and PTP-Z deficiency were performed by 
the laboratory of Dr. Vicki Kelley (Brigham & Women’s Hospital, MA, USA).  C57BL/6 
wild type, Il-X-/-, and IL-XR-/- mice were obtained. For all experiments, male mice at 8–12 
weeks of age were used. Mice were given intraperitoneal injections of 150μl of K/BxN 
sera on day 0 and 2 to induce inflammation and spontaneous arthritis. The more inflamed 
forepaw from each mouse was harvested on Day 10 after the injection of the serum. For 
assessment of correlation between inflammation and erosion severity, 14 week old male 
C57BL/6 mice were injected with 150μl of K/BxN sera on day 0, 2 and 7 and harvested on 
day 14. Both forepaws were harvested. In all experiments, inflammation was assessed by 
clinical scoring and by measurement of the change in forepaw and ankle thickness using 
calipers. All experimental procedures were approved by the Institutional Animal Care and 
Use Committee of the Harvard Center for Comparative Medicine. 
2.1.2 Micro-computed tomography (micro-CT)  
 Analysis of bone erosion: Forepaws were scanned on a Scanco μCT-35 with an 
isotropic voxel size of 7 μm and 3-dimensional images were generated with software 
supplied by the manufacturer using a global threshold that set the bone/marrow cut-off at 
367.8 mg HA/cm3. Periarticular erosions were scored by an observer blinded to genotype 
using a semi-quantitative method as previously described40. Briefly, four sites in the wrist 
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(ulnar epiphysis and bases of the third, fourth, and fifth metacarpals) were scored for 
severity of erosion using a scale of 0-3, with 3 indicating the most severe erosion.  
2.1.3 Statistical Analysis  
 Statistical analysis was performed with GraphPad Prism version 7. Erosion scores 
were analyzed using a Kruskal-Wallis test with a Dunn post-test. 
 
Figure 5. Mouse paw erosion scoring method at the joints. A. locations on the each paw that scored are 
circled red. B. arrows pointing to examples of scoring based on the following scale: score of 0 for normal 
cortical bone; score of 1 for a large cortical erosion with few perforation into the marrow cavity; score of 2
for a large cortical erosion a small perforation; score of 3 for a large cortical erosion with a large perforation 
or multiple small perforations. The score of all locations were added at the end to give a final score of 
erosion for each paw. C-D. The erosion scoring from two independent observers were recorded and 
compared. It could be concluded that this method is reproducible and reliable for scoring of STA mouse 
paws in this project. Reprinted with permission from O’Brien et al40.  
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2.2. Human osteoclast in rheumatoid arthritis  
2.2.1 Human OC cultures  
 Total human peripheral blood mononuclear cells (PBMC) obtained from 
leukoreduction collars were frozen in 90% DMSO, 10% serum according to a standardized 
freezing protocol. Frozen samples were thawed and cultured in human-M-CSF (h-M-CSF, 
25ng/mL) for 5 days in petri dishes (Corning, 100×10 mm) at a density of 1.2×106 cells/mL. 
This leads to the expansion of myeloid cells that can act as OCP. Expanded myeloid cells 
were isolated on day 6. Subsequently, cells were cultured at a density of 3.5×106 cells/mL 
with h-M-CSF (25ng/mL) plus TNF and IL-6 or either cytokine alone. H-M-CSF expanded 
PBMCs cultured with h-M-CSF (25ng/mL) and human-RANKL (50ng/mL) were used as 
positive controls. The culture media was changed every 3 days. D-MEM media was 
supplemented with L-glutamine (2mM), Penicillin/Streptomycin (50000units), and 10% 
FBS before adding cytokines for OCP expansion and differentiation.  
 OC differentiation was quantified after 14 days by the standard method of staining 
fixed cultures for tartrate-resistant acid phosphatase (TRAP) activity and counting 
multinucleated TRAP-positive cells. TRAP degrades skeletal phosphoproteins including 
osteopontin (OPN) and is essential for the bone-resorptive functions of OCs. Though used 
as a marker of mature OC, TRAP is expressed by other cell types including macrophages 
and dendritic cells69. Since TRAP secreted from OCs into the extracellular milieu, the 
activity of secreted TRAP enzyme in culture supernatants was determined as a 
confirmatory assay70.  
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Table 1. Cytokines used for human osteoclast cultures 
Name Company Concentration 
Recombinant Human M-CSF R&D System 25ng/mL 
Recombinant Human RANKL R&D System 50ng/mL 
Recombinant Human TNF R&D System 50ng/mL 
Recombinant Human IL-6 PeproTech 50ng/mL 
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2.3. Absence of metabolic stimulation:  Osteoclast-specific Tsc2 deletion in mice 
causes a high bone mass, with clinical implications for bone lesions in Tuberous 
Sclerosis Complex 
2.3.1 Generation of Ctsk-Cre;Tsc2fl/fl mice 
 Cre-loxP recombination was used to generate mice with conditional deletion of 
Tsc2 in mature OCs. Cre-loxP is a site-specific recombinase (SSR) technology that allows 
for gene knockout when triggered by an external stimulus71. The Cre protein is a site-
specific DNA recombinase that catalyzes the recombination of two specific loxP sites on a 
DNA strand. Genes in between the two loxP sites are excised out and will not be transcribed. 
For the purpose of studying the effect of Tsc2 deletion in OC, we crossed mice with a 
“floxed” (fl) allele of the Tsc2 gene, eg where a portion of the Tsc2 gene is flanked by loxP 
sites to mice expressing an OC specific Cre.  These mice express Cre under the control of 
the Cathepsin K (Ctsk) promoter72.  Cathepsin K is a lysosomal enzyme derived primarily 
from mature, active OCs. These Ctsk-Cre mice were crossed with Tsc2fl/fl mice73 to 
generate Ctsk-Cre;Tsc2fl/fl mice, also referred to as Tsc2ΔOC mice.  In these mice, cells in 
which Ctsk is expressed (almost exclusively OC) will also express Cre protein and delete 
Tsc2.  Tsc2fl/fl mice – without the presence of Cre – were used as wild type controls. 
CtskCre,Tsc2fl/- mice with Tsc2 floxed on one allele were generated and used as 
heterozygous controls. All mice strains were on the C57BL/6 background. All experiments 
were performed in accordance with American Associaton for Laboratory Animal Science 
(AALAS) guidelines and under the supervision of the Harvard Center for comparative 
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medicine Institutional Animal Care and Use Committee (IACUC). Tsc2+/- mice were 
generated in by the Kwiatkowski laboratory74.  
2.3.2 ELISA for Serum CTX-I, and P1NP  
 Mouse serum was derived from blood samples collected by cardiac puncture using 
serum separation tubes (Becton Dickinson). Bone turnover markers, serum C-terminal 
telopeptides (CTX-I) and Procollagen type 1 propeptides (PINP), were quantified using 
enzyme immunoassay assays (Immunodiagnostics Systems). All ELISAs were read with 
Synergy H1 Hybrid Reader (Biotek). 
2.3.3 Isolation and culture of OCP 
 Mice were euthanized with CO2, and cardiac puncture or cervical dislocation were 
used as secondary methods to confirm death before further procedures. OC were cultured 
from bone marrow precursors as follows. Mouse femurs and tibia were harvested, from 
which bone marrow was isolated by flushing with HBSS (with Ca2+/Mg2+). The cell 
suspension was treated with RBC lysis buffer and resuspended in sorting media αMEM 
containing 10% FBS (Hyclone). Cells were cultured in petri dishes with media containing 
M-CSF (40ng/mL) for 3 days, then cells adherent to the dish surface were collected – due 
to properties of the petri dish surface, OCPs tend to stay adherent while other cell types 
(lymphocytes, fibroblast, etc) from the suspension stay afloat. The myeloid cell precursors 
were then collected and resuspended in M-CSF (20ng/mL) and RANKL (10ng/mL) at a 
density of 8×104 cells/mL on culture plates described in Table 3. Cell culture media was 
changed every 3 days. Cultures were monitored for differenatiation and harvested when 
mature OC were observed, typically day 5-7.  
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 OC were cultured from spleen precursors as follows. Single cells suspensions were 
prepared by mechanical disruption and passage through a 0.22μm filters. The cell 
suspension was treated with RBC lysis buffer, then cultured in petri dishes in the presence 
of M-CSF (40ng/mL) for 5 days to expand the OCP population. Splenic myeloid 
progenitors were collected and plated in the same method as described above. Cytokines 
and culture additives for mouse OC culture media are listed in Table 2.  
Table 2. Cytokines and media used for mouse osteoclast cultures 
Name Company Concentration 
Recombinant mouse M-CSF R&D Systems 40ng/mL (before expansion)  
or 20ng/mL (after expansion) 
Recombinant mouse RANKL R&D Systems 10ng/mL 
 
 The staining of an OC-specific marker tartrate-resistant acid phosphatase (TRAP) 
and the visualization of OC pit formation were used to quantify OC differentiation and 
function, both of which are standard methods in the field (3). TRAP assays were used in 
the method described in 2.2.1, and TRAP+ cells were manually counted. Corning Osteo 
Assay Surface multiple well plates were used to characterize and assay OC-mediated bone 
resorption. The assay wells are coated with a layer of proprietary synthetic inorganic bone 
mimetic, which could be digested by active OCs once they form in the culture75. The area 
of resorption pits divided by the area of the well was then calculated with Image J., and the 
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resulting percentage reflects the ability of cultured cells to resorb mineralized matrix and 
form resorption pits on the surface of the assay. Pate types and treatment for bone marrow 
spleen OCP cultures are listed in Table 3. 
Table 3. Plate types and functions for bone marrow and spleen osteoclast cultures 
Plate type Area/well 
(cm2) 
Treatment Purpose 
96 well 
(Flat bottom) 
0.32 TRAP staining Detection of multinucleated TRAP+ OC 
24 well 1.9 TRIzol® Reagent RNA extraction 
12 well 3.8 TRIzol® Reagent Protein extraction 
Corning 
resorption 
assay 
0.32 Silver nitrate, 
pyrogallol 
Area of resorption by osteoclast as a 
measurement of activity level 
 
2.3.4 Bone RNA Isolation and Real-Time PCR 
 TRIzol® Reagent is used to isolate RNA, DNA, and proteins from bone and OC 
samples (Thermofisher). Bones were homogenized in ice-cold TRIzol using bullet blender 
beads (Next Advance), while OCs were directly dissolved in TRIzol. RNA was isolated 
using a standard TRIzol protocol; quantity and quality of the RNA were measured with 
Synergy H1 Hybrid Reader (Biotek). Samples obtained after TRIzol extractions were 
further purified using the RNeasy Plus Micro Kit with on-column genomic DNA-digest 
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(Qiagen). Affinity Script quantitative PCR (qPCR) cDNA Synthesis Kit (Agilent 
Technologies) and was used to generate cDNA. Real-time PCR was performed on StepOne 
Plus Realtime PCR Machine (Applied Biosystems), using Fast SYBR Green Master Mix 
(Thermo Fisher Scientific). Gene expression was determined relative to the housekeeping 
gene Hprt (Hypoxanthine Phosphoribosyl Transferase). Fold change in gene expression 
between experimental and control samples was calculated by the delta-delta-Ct method.  
2.3.5 Micro-CT  
 After serial fixation in 4% (g/100 mL) paraformaldehyde and 70% (vol/vol) ethanol, 
femurs were scanned using a μCT 35 (Scanco Medical AG). Scans were conducted in 70% 
ethanol using a voxel size of 7 μm, X-ray tube potential of 55 kVp, intensity of 0.145 Ma, 
and integration time of 600 ms. A region beginning 0.35 mm proximal to the growth plate 
and extending 1 mm proximally was selected for trabecular bone analysis. A second region 
0.6 mm in length and centered at the midpoint of the femur was used to calculate diaphysis 
parameters. The region of interest was thresholded using a global threshold that set the 
bone/marrow cutoff at 352.3 mg HA/cm3 for trabecular bone and 589.4 mg HA/cm3 for 
cortical bone. 3D microstructural properties of bone were calculated using software 
supplied by the manufacturer. Bone length was measured using the scout view feature.  
 Skeletal surveys were performed using whole body micro-CT scan on 12 month-
old female Tsc2+/- mice. Sclerotic lesions were identified as localized increase in signal 
intensity on the scan.  
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2.3.6 Bone biomechanical testing 
 In collaboration with Shefelbine laboratory, biomechanical properties of 
CtskCre;Tsc2fl/fl bone were assessed. Three point-bending experiments were performed on 
an Instron test machine (Instron 5966) to compute the properties of CtskCre;Tsc2 fl/fl femurs 
in a post-processing analysis. 8 bones from male mice were tested (5 mutant and 3 control) 
in a displacement control mode and a displacement rate of 0.01 mm/s. Load was monitored 
by a 50 N load cell. Each femur was loaded in the anterior-posterior orientation on a micro 
three-point bending set-up (plunger radius 0.25 mm and a span length 6 mm as shown in 
Figure 6). The end of the test was marked with 40% load drop in each case. A custom 
MATLAB code (Matlab, MathWorks) was used to analyze the load-displacement data for 
each sample and compute the bending stiffness (N/mm), yield load (N), ultimate load (N), 
and fracture energy (mJ) for every specimen. 
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2.3.7 Cell lysates and Immunoblot  
 For immunoblot analyses cells were washed with ice-cold PBS and lysed on ice in 
1x RIPA buffer (Cell Signaling Technology) with phosphatase and protease inhibitors 
(Sigma). Lysates were normalized to protein concentration, denatured with loading buffer, 
and resolved by electrophoresis on a 4-12% Bis-Tris gel (Invitrogen). Proteins were 
transferred to PVDF membranes, blocked in 5% BSA or nonfat milk for 1h probed with 
primary antibodies (1:1000) in 1x TBST buffer (Cell Signaling Technology) overnight at 
4°C. Membranes were washed with TBST and incubated with secondary antibody 
(1:10000) for 1h at room temperature and chemiluminescence was visualized using Super 
Signal (Pierce) and the SynGene G-BOX gel documenting system. The following 
antibodies were used: phospho-p70S6K (Thr 389) (Cell Signaling Technology), Actin 
Figure 6. Micro three-point bending fixture. 
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(Cell Signaling Technology), TS6K (Cell Signaling Technology), and Cathepsin K 
(abcam). 
2.3.8 Statistical Analysis  
 Statistical analysis was performed with GraphPad Prism version 7. Statistical 
significance was determined by Student’s t-test. 
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RESULTS 
3.1. The inflammatory cytokine IL-X in a mouse model of inflammatory arthritis 
 As discussed above, IL-X is produced by FLS near the joints and can act as a ligand 
for OC-promoting CSF-1R, an essential receptor for myeloid cell proliferation and survival. 
We anticipated that mice deficient in IL-X would develop less severe arthritis when 
induced with serum from K/BxN mice. However, in contrast to our hypothesis, forepaw 
erosions in mice deficient for either Il-X or its receptor Il-XR had higher erosions score than 
wild-type (WT) mice (Figure 7). The difference between Il-X-/- mice and WT mice was 
highly statistically significant (p=0.0054 for Il-X-/- vs WT), as was the difference between 
the Il-xr-/- mice and WT (p=0.0498). Thus, deficiency in either IL-X or IL-XR results in 
more severe erosions in the forepaw, which is reflected by the images with more evident 
perforations and cortical erosions on ulnar bone and metacarpals.  
 
Figure 2 
 31 
 
Figure 7. IL-X-/-, and IL-XR-/- mice have more severe erosions than wild-type (WT) mice. The erosion scores 
are graphed with each point representing one paw (upper panel). Mean with SEM is plotted in the graph 
and significance determined by Kruskall Wallace test with a Dunn post-test. Representative 3D 
reconstruction images for each genotype are shown (bottom panel).For consistency, all left paws were 
chosen to represent the scores.   
 As IL-X-/- and IL-XR-/- mice developed more severe inflammation than wild-type 
control mice in this experiment, we asked whether severity of inflammation correlated with 
erosion score.  We compared the change in paw thickness from day 0 to day 14 of STA for 
each of 20 paws from C57BL/6 strain WT mice and compared this to the erosion score for 
each individual paw at day 14.  We find that erosion score is highly correlated to 
inflammation as measured by the change, or delta, in paw thickness, as demonstrated in 
Figure 8.   
 
 
Figure 8. Inflammation and erosion score are highly correlated. Delta paw thickness for each individual 
paw as a measure of inflammation is graphed versus erosion score for that paw for n=20 paws. Increased 
thickness indicates increased inflammation. The Pearson correlation coefficient, r, is 0.8633, p<0.0001. 
 
Figure 3 
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3.2. Human osteoclasts in rheumatoid arthritis  
 The work of testing out the ideal protocol for human OC culture is in progress. The 
cultures have been suboptimal with some TRAP+ cells but lack of mature active OC after 
14 days of culture.   
 Protocol adjustents to improve differentiation include changing the OCP density 
and plate types. Since myeloid cells committed to OC lineage were more adherent to glass 
surfaces than other cells types, glass chambers were used for cultures as an additional step 
of purification. However, the result was similar than to 96-well plates shown in Figure 9 
above. Potential reasons for lack of differentiation and future directions for further 
experiments are discussed in section 4.2. 
 
A B 
Figure 9. Human osteoclast assays in 96-well plates after TRAP staining. A. myeloid cells were cultured in 
media with MCSF (25ng/mL) only as control. Clusters (pointed by arrow) are due to unknown reasons. B.
myeloid cells cultured in MCSF (25ng/mL) and RANKL (50ng/mL) shows little differentiation into 
osteoclasts. However, several round, multinucleated cells were suspected to be early osteoclasts. Spindle-
shaped macrophages can be seen dispersed throughout the well. Clusters of cells are more prevalent than 
in control wells.  
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3.3. Absence of metabolic stimulation:  Osteoclast-specific Tsc2 deletion in mice 
causes a high bone mass, with clinical implications for bone lesions in Tuberous 
Sclerosis Complex 
3.3.1 Mice heterozygous for Tsc2 develop sclerotic bone lesions 
 Sclerotic bone lesions are characterized by a local increase in bone mineral 
density.  Sclerotic lesions were identified in 12 month old Tsc2+/- mice in the pelvis and 
vertebrae, which are also the most common location of lesions in TSC patients. Lesions 
were identified in 4/4 Tsc2+/- mice and 0/2 Tsc2+/+ littermates. Example lesions are 
shown in Figure 10.  
 
Figure 10. Sclerotic bone lesions are found in aged Tsc2+/- mice. 12 month old Tsc2+/- and Tsc2+/+ 
littermates were imaged by microCT, pixel size 15μm. Resulting 2D images were reviewed by 2 
independent reviewers blinded to genotype. Representative images of lesions (white arrows) and 
corresponding anatomic position of controls are shown. 
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3.3.2 Deletion of Tsc2 results in hyperactivation of mTORC1 in OCs 
 Bone marrow and splenocytes from CtskCre;Tsc2fl/fl (Tsc2ΔOC) mice were 
harvested and cultured in the presence of M-CSF and RANKL, with cultures in M-CSF 
only as controls. Differentiation were estimated by visualization using light microscopy. 
Once differentiation was observed, usually after 6 days of cultures, cells were harvested 
using 4% paraformaldehyde. Wildtype and Tsc2ΔOC mice have similar degrees of 
commitment to the OC lineage, as demonstrated by their similar expression level of 
Cathepsin-K, a marker of OC maturation. As shown in Figure 11, western blot analysis of 
S6K phosphorylation in Tsc2ΔOC spleen derived OC lysates demonstrates a 2-fold 
increase in S6K phosphorylation level compared to a littermate control. Thus, deletion of 
Tsc2 in OCs results in the expected increase in mTORC1 activity.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. mTORC1 hyperactivation in TSC deficient spleen derived osteoclasts. A. Western blot 
showing increased phosphorylated S6K (pS6K) and total S6K (tS6K) in spleen monocyte derived 
osteoclasts in Tsc2ΔOC and Tsc2fl/fl controls. Cathepsin K expression confirmed the osteoclast lineage 
commitment in both genotypes; actin loading control. B. Increased pS6K /tS6K ratio is consistent with 
increased mTORC1 activity in Tsc2ΔOC osteoclasts. Densitometry of the immunoblot bands was 
evaluated with ImageJ. 
B. 
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3.3.3 CtskCre;Tsc2fl/fl mice have a high bone mass phenotype and increased resistance to 
fracture 
To evaluate if loss of Tsc2 results in a bone phenotype, femoral bones from cohorts 
of male and female mice at 3 months of age were analyzed by micro-CT. Parameters that 
were examined included bone volume fraction (BV/TV), trabecular bone marrow density, 
trabecular number and spacing, cortical thickness and porosity, and periosteal area. 
Increased trabecular bone mass and cortical thickness is seen in both males and females by 
3 months of age, with a suggestion that the phenotype may be stronger in females (Figure 
12. A-I). All the bone parameters examined by micro-CT are significantly increased in 3 
month-old Tsc2ΔOC mice compared to a pooled control group of wild type and 
heterozygous mice (Figure 12. A-C). For trabecular bones, BV/TV (0.3732 ± 0.03488 vs 
0.1100 ± 0.01001 vs; p< 0.0001) and trabecular bone marrow density (BMD, 969.6 ± 8.077 
mg of HA/ cm3 vs 896.4 ± 5.492 mg of HA/ cm3; p < 0.0001) are significantly increased. 
Consistent with this, trabecular number is also increased (5.687 ± 0.3008/mm vs 4.377 ± 
0.2036/mm; p= 0.0009), along with trabecular thickness (0.08575 ± 0.004971mm vs 
0.04244 ± 0.001003 mm; p < 0.0001) and decreased trabecular spacing (0.1681 ± 
0.008263/ mm vs 0.2320 ± 0.01158/ mm; p= 0.0003). For cortical bones, cortical thickness 
(0.2418 ± 0.006798 mm vs 0.1944 ± 0.003965 mm; p < 0.0001) and periosteal area (1.344 
± 0.05185 mm2 vs 1.041 ± 0.02862 mm2; p < 0.0001) were both significantly increased. 
Cortical porosity (0.09158 ± 0.003486 vs 0.1032 ± 0.001873; p= 0.0043) and cortical BMD 
(1182 ± 3.540 mg of HA/cm3 vs 1207 ± 4.208 mg of HA/cm3; p= 0.0001) are decreased, 
and cortical BMD did not show any difference at 3 month old.  
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Interestingly, mice appear to continue to accrue bone with aging, as bone mass and 
cortical thickness are increased even further in a cohort of 9 month-old male mice (Figure 
12. D-F). Trabecular and cortical bone parameters of the right femur of 9 month-old mice 
were evaluated using micro-computed tomographic imaging (micro-CT). All parameters 
Figure 12. CtskCre;Tsc2fl/fl mice of both sexes demonstrate progressive increase in trabecular and 
cortical bone with age and increased bone strength and toughness. A-C. Trabecular BV/TV, cortical 
thickness (CtTh) and tissue bone mineral density (BMD) determined by ex vivo microCT in 3 month old 
CtskCre;Tsc2fl/fl mice (blue squares) compared to Tsc2fl/fl littermate controls (black circles). D-F. Bone 
parameters for 9 month-old male mice. G-I. Biomechanical testing shows increased bone toughness 
(stiffness), load to fracture (ultimate load) and work to fracture. Each symbol represents one animal; 
significance determined by Student’s t-test, * p<0.05, **p<0.005, ***p<0.0005. 
D E F 
G H I 
 37 
 
were significantly increased in Tsc2ΔOC mice compared to Tsc2fl/fl (wild type).  Examining 
cortical bone, we found that at 9 months of age Tsc2ΔOC mice have increased cortical 
thickness (0.2702 ± 0.01125mm vs 0.2130 ± 0.01277mm; p<0.02), periosteal 
circumference (15.40 ± 0.8008 mm vs 9.430 ± 0.2006 mm; p<0.01), and periosteal area 
(2.843 ± 0.1219 mm2 vs 2.151 ± 0.03554 mm2; p<0.01). Cortical porosity was unchanged 
(0.07769 ± 0.005264 vs 0.07928 ± 0.005511; p= 0.8696), Trabecular bone is also 
dramatically increased in Tsc2ΔOC mice, as measured by BV/TV (bone volume/ tissue 
volume) (0.4981 ± 0.04740 mm2 vs 0.1397 ± 0.01306 mm2; p=0.0007) and trabecular 
BMD (bone mineral density) (961.9 ± 9.300 vs 892.9 ± 6.340; p=0007). Other trabecular 
parameters were altered consistent with the observed increase in BV/TV, with an increase 
in trabecular number (7.675 ± 0.8254 vs 3.930 ± 0.1093, p=0.01) and trabecular thickness 
(0.09413 ± 0.004678 vs 0.05095 ± 0.0008694 mm, p<0.0001), and decrease in trabecular 
spacing (0.1541 ± 0.01738 vs 0.2417 ± 0.007311 mm; p=0.01). The progressive increase 
from 3mo old to 9mo old indicates that the increase in bone formation and accretion of 
bone mass is likely to be progressive throughout the lifetime of the animal. 
 In addition to micro-CT, biomechanical evaluation of the mutant bones using the 
three-point bending tests demonstrated have increased work to fracture for CtskCre;Tsc2fl/fl 
femurs, suggesting that increased mTORC1 in Ctsk-expressing cells drives formation of 
good quality bone (Figure 12. G-I). Mechanical properties of male Tsc2fl/fl and Tsc2ΔOC 
samples were calculated and analyzed by Shefelbine lab. Compare the results between 
Tsc2fl/fl and Tsc2ΔOC specimens, student t-test was used in each case. All measures were 
significantly different between the groups and higher in Tsc2ΔOC samples (except for the 
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elastic to plastic energy ratio). Stiffness, yield load and the ultimate load is increased in 
Tsc2ΔOC bones and fracture energy is also much higher in Tsc2ΔOC samples compared to 
Tsc2fl/fl indicating that Tsc2ΔOC samples are stronger and fracture toughness is increased 
in these bones.  
3.3.4 Tsc2 deficiency in OCs has no effect on differentiation or function 
 In order to understand the paradoxical increase in bone mass in mutant mice, further 
analysis was done to determine whether OC or OB functions were altered by the deletion 
of Tsc2 or the hyperactivity of mTORC1. Loss of Tsc2 in OCs had no significant effect on 
OC differentiation in vitro, since the bone marrow myeloid (BMM) precursor cells were 
able to differentiate into mature OCs, as assessed by TRAP+ staining. Moreover, the 
number of Tsc2ΔOC derived OCs was comparable to control derived OCs. Similar results 
were obtained from cultures of splenocyte-derived OCs (Figure 13). To further evaluate 
the function of the TSC2 deficient OCs in vitro, the secretion of TRAP in the cultured 
media by bone marrow derived OCs and spleen derived OCs from both CtskCre-/-;Tsc2fl/fl 
and Tsc2ΔOC mice was measured. The media was stained for TRAP and the absorbance 
was measured at 405nm. No significant differences were observed between the absorbance 
of culture media of Tsc2ΔOC bone marrow derived OCs and control (2.906 ± 0.4061 vs 
3.108 ± 0.7515, p= 0.8095), as well as in Tsc2ΔOC spleen derived OCs and control (1.851 
± 0.4970 vs 2.441 ± 0.4525, p= 0.4756).  
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Figure 13. Osteoclast number and activation of Tsc2ΔOC mice are unchanged in vitro. A. osteoclast 
differentiation from Tsc2ΔOC splenic monocytes as assessed by TRAP+ multinucleated cells (MNC) B. TRAP 
secretion in bone marrow and spleen derived osteoclasts. C. To measure TRAP activity, p-NPP was added 
to cell culture supernatant and absorbance was measured at 405nm. WT group n=3 vs Tsc2Δosteoclasts 
n=2.  Each symbol represents the assay absorbance value of cells derived from one animal; significance 
was determined by Student’s t-test. Mean and Standard Deviation for each group are represented in the 
graphs.    
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In vitro, OC resorption activity was also examined by plating BMM and splenocytes on 
Corning Osteo Resorption assays. There was no significant difference between the areas 
of resorption from wildtype controls and Tsc2ΔOC mice. Three experiments were 
performed, giving the same results (Figure 14). This again suggests that defective OC 
resorptive function is unlikely to explain the high bone mass phenotype in Tsc2ΔOC mice. 
Other possible explanations would include increased OB activities induced either directly 
by unanticipated Cre expression and Tsc2 deletion in an OB population or indirectly by 
specific deletion of Tsc2 in Ctsk-expressing cells. 
A. 
B. 
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 In vivo OC differentiation was assessed in femur histological sections to determine 
if Tsc2 deficiency altered. Nine month-old male Tsc2ΔOC mice appear to have normal OCs, 
despite the TSC2 deletion, as assessed by TRAP staining. Despite an apparently normal 
formation of OCs, an increase in bone deposition it is clearly visible in the femur histology 
of Tsc2ΔOC mice, with a decrease in bone marrow space, in both epiphysis and diaphysis 
(Figure 15). Moreover, relative mRNA expression of Cathepsin K as a marker of mature 
OC in whole bone was found to be slightly but significantly increased (2 fold) in 3 month 
old Tsc2ΔOC male mice. This is consistent with the in vivo and in vitro TRAP+ staining 
showing the formation of mature OCs, and further confirms that TSC2 loss in mature OCs 
does not inhibit OC formation or ability of synthesize at least some of the lysosomal 
enzymes necessary for the bone resorption activity (Figure 16).  
 
Figure 14. Osteoclast-specific deletion of Tsc2 does not alter osteoclast resorption functions, as shown 
by osteo resorption assays. Osteoclast activity from 3mo male and female splenocytes were cultured on 
Corning resorption assays for their digestive activity. A. Transparent resorption pits are visible post-
treatment with silver nitrate and pyrogallol, with brown areas indicating incomplete resorption and black 
areas without any osteoclast activity. BMM Osteo Assays have similar results (not shown). B. Resorption 
areas of activated osteoclast in vitro is unchanged in Tsc2ΔOC mice compared to the wild type. Each dot 
represents one animal; data is representative of three individual experiments. Resorbed areas are 
visualized using light microscopy and measured using Image J; significance was determined by Student’s t-
test. Mean and standard error of mean for each group are represented in the graphs. 
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 Although OCs formed in vitro in Tsc2ΔOC mice, it is possible that Tsc2ΔOC OCs 
do not resorb normally, which would explain the high bone mass phenotype in the mutants. 
To evaluate the in vivo activity of OCs in Tsc2ΔOC mice, CTX-I level was measured as a 
Figure 15. Increased trabecular bone in 9 moth old Tsc2ΔOC mice with normal osteoclasts in vivo. 
Staining of femur sections from 9 month-old mice for tartrate resistant acid phosphatase (TRAP+) activity  
shows the presence of active osteoclasts  in Tsc2ΔOC mice (low panel) and WT littermates (top panel). 
Arrows identifies TRAP + osteoclasts (digital enlargement of boxed area on left panel). 
Figure 16. mRNA relative expression of Cathepsin K in 3 month old male Tsc2ΔOC  mice. Tsc2fl/fl n=5 vs 
Tsc2ΔOC n=6. HPRT was used as housekeeping gene. RNA was extracted from right femur. Each symbol 
represents one animal; significance was determined by Student’s t-test. Mean and Standard Deviation 
for each group are represented in the graphs. 
Tsc2fl/fl 
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reflection of OC activity. CTX-I is the C-terminal telopeptide sequence of type I collagen, 
the predominant form of collagen found in bone. This telopeptide is cleaved by the activity 
of OCs during bone resorption and released into the serum. Its serum levels are proportional 
to OC activity at the time blood sample is drawn. CTX-I was normal in 9 month old male 
Tsc2ΔOC mice (30.05 ± 11.10 ng/ml vs 74.83 ± 40.39 ng/ml,  p<0.0001) compared to WT 
+ Heterozygous and decreased but not significantly in Tsc2ΔOC females compared to WT 
+ Heterozygous (33.04 ± 7.591 ng/ml vs 25.29 ± 2.242 ng/ml, p=0.23). Therefore, 
defective OC resorptive function is unlikely to explain the high bone mass phenotype in 
Tsc2ΔOC mice.  
 The serum level of CTX-I was measured in serum of 3 month old mice as well 
(Figure 17). As seen for the 9 month-old female cohort, serum CTX-I was found 
comparable between Tsc2ΔOC mice and the control group in both females  (15. 35 ng/ml 
vs 22.86 ng/ml, p= 0.3504) and males (14.9 ng/ml vs 14.49 ng/ml, p= 0.9226).  
Figure 17. CTX-I levels in male and female mice are unchanged in Tsc2ΔOC mice. A. Serum CTX-I measured 
with competitive ELISA in 3 month old Tsc2fl/fl and CtskCre;Tsc2fl/fl male (Tsc2fl/fl n=7 and Tsc2ΔOC n=5)and 
female (Tsc2fl/fl n=7 and Tsc2ΔOC n=6). B. Serum CTX-I measured with competitive ELISA in 9 month old 
Tsc2fl/fl and CtskCre;Tsc2fl/fl mice male (Tsc2fl/fl n=5 and Tsc2ΔOC n=5)and female (Tsc2fl/fl n=6 and Tsc2ΔOC 
n=11). There was no significant difference between the genotypes in either sex or age group. Each symbol 
represents one animal; significance was determined by Student’s t-test. Mean and standard error of mean
for each group are represented in the graphs.  
A. 
 
B. 
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3.3.5 Osteoblast activity is increased in Tsc2ΔOC mice 
 The function of OBs, the cells responsible for the deposition of bone matrix, was 
then examined as the next step to understand the cell type responsible for high bone mass 
phenotype by measuring serum P1NP levels. P1NP  is the N-terminal propeptide of 
procollagen 1. In bone, collagen is synthesized by OBs in the form of procollagen, and the 
propeptide is removed by specific proteinases before the individual collagen molecules can 
assemble into the triple helix that forms the collagen fibril. The propeptide can be found in 
the circulation and its concentration in the serum reflects the synthesis rate of collagen type 
I and consequently OB activity76. Therefore, the concentration of P1NP in both 9 month 
old male and female mice were measured.  The serum concentration of procollagen type I 
N propeptide (P1NP), a measure of OB activity, was elevated in Tsc2ΔOC  male (55.61 ± 
10.31 ng/ml vs 82.48 ± 21.83 ng/ml, p<0.0001) and female (57.24 ± 16.38 ng/ml vs 100.74 
± 10.81 ng/ml, p=0.04)  mice compared to CtskCre-/-;Tsc2fl/fl and CtskCre;Tsc2fl/- mice, 
suggesting that loss of Tsc2 in OCs stimulates bone formation by OBs (Figure 18). Serum 
P1NP levels in the 3 month-old cohort is also highly elevated in mutant compared to control 
mice, similar to what was seen in the 9 month-old cohort. Bone formation was increased 
as measured by P1NP in both females (66.64 ng/ml vs 165.5 ng/ml, p= 0.002) and males 
(71.83 ng/ml vs 192.9 ng/ml, p= 0.004). Therefore, the high bone mass phenotype – even 
at early stage of life – is the result of a hyperactivation of the OBs, even though the loss of 
Tsc2 function is specific to Cathepsin- K expressing OCs. These results, in combination 
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with the OC activity data, lead to the hypothesis that alteration in the coupling of OC 
activity to OB function is responsible for the increased bone formation in Tsc2ΔOC mice. 
3.3.6 Coupling factor CTHRC1 is increased in Tsc2ΔOC mice 
 A panel of putative OC-OB coupling factors including CTHRC1, SPHK1, and 
SPHK2 was examined. These factors have been suggested to increase bone formation, 
although the exact mechanisms and cell sources are unknown. Expression of Cthrc1 was 
found to be significantly elevated in bones from 9-month-old CtskCre;Tsc2fl/fl mice, while 
the other factors did not show significant difference from Tsc2fl/fl mice. With this 
preliminary result, we next focused on Cthrc1 expression as a possible factor explaining 
the increase in bone formation in mutant mice. The experiment was repeated with a cohort 
of 3-month-old male mice. Bones from three pairs of littermates were harvested, and their 
bone CTHRC1 and mRNA levels were examined. The level of Cthrc1 mRNA was found 
Figure 18. P1NP levels are significantly increased in male and female Tsc2ΔOC mice. A. Serum P1NP-I 
measured with competitive ELISA in 3 month old male (Tsc2fl/fl, Tsc2fl/- n=8 vs Tsc2ΔOC n= 5) and female 
(Tsc2fl/fl, Tsc2fl/- n=8 vs Tsc2ΔOC n=7). B. Serum P1NP-I measured with competitive ELISA in 9 month old 
male (Tsc2fl/fl, Tsc2fl/- n=9 vs Tsc2ΔOC n=18) and female (Tsc2fl/fl, Tsc2fl/- n=6 vs Tsc2ΔOC n=11). There was a 
significant increase in both age periods, and particularly in male mutant mice. Each symbol represents one 
animal; significance was determined by Student’s t-test, * p<0.05, **p<0.005, ***p<0.0005. Mean and 
standard deviation for each group are represented in the graphs.   
A. B. 
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to be increased 9.6 fold (Tsc2fl/fl relative mRNA expression 1.101 ± 0.2127 and Tsc2ΔOC 
9.646 ± 1.731 n=6, p= 0.0016) as demonstrated in Figure 19, panel C.  
  
 As shown in Figure 19, bone expression of CTHRC1 is increased at both the mRNA 
and protein level in CtskCre;Tsc2fl/fl compared to Tsc2fl/fl controls. The data presented here 
lead to our central hypothesis for future analysis: loss of Tsc2 in OCs and the concomitant 
increase in mTORC1 activity result in a high bone mass (HBM) phenotype due to 
CTHRC1-mediated stimulation of bone formation. The approaches laid in out in future 
directions (section 4.3.6) will allow us to address whether the observed HBM originates 
from the OC or an alternative Ctsk-expressing cell. Questions regarding the biological 
mechanism of the candidate anabolic factor CTHRC1 and in vitro OB differentiation and 
will also be addressed.  
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Osteoclast                                                    Osteoblast 
Figure 20. Model showing the likely effect of osteoclast-specific Tsc2 deletion in mice. Top panel: in 
normal osteoclast (Tsc2fl/fl), mTOR activity leads to normal level of CTHRC1 production and osteoblast 
differentiation. Bottom panel: The hypothesis of this project is that in Tsc2ΔOC mice, the absence of 
inhibition of TSC2 complex on mTOR indirectly promotes the expression of CTHRC1. Subsequently, 
osteoblast differentiation and activation are also increased, leading to increased bone formation and high 
bone mass phenotype with strong bones observed.  
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DISCUSSION 
4.1. The inflammatory cytokine IL-X in a mouse model of inflammatory arthritis 
 Contrary to our hypothesis, it was found that bone erosion in an inflammatory 
arthritis model is more severe when IL-X is absence than when IL-X is present. Therefore, 
it is safe to conclude that IL-X is not required for the generation of OCs in inflammatory 
arthritis. The higher erosion scores in IL-X-/- and IL-XR-/- groups could be explained by the 
more severe inflammation observed in these groups, as we found that erosion score 
positively correlates with inflammation severity. The erosion scores observed in wild type 
mice in this experiment were lower than what we have previously reported40. This could 
be due to the differences in the protocol for inducing STA – forepaws were harvested on 
day 10 instead of day 14, allowing less time for erosions to develop. Variation in the 
potency of K/BxN serum used could also lead to the different degrees of inflammation.  
Further analysis would include scanning and scoring of the other forepaw from each mouse. 
Histologic analysis could also be conducted to detect and quantify OC formation in mutant 
mice compared to wild-type. This work demonstrates that although IL-X is induced in the 
synovium in inflammatory arthritis and can activate the cFms receptor, it does not play a 
significant role in OC formation in inflammatory arthritis. 
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4.2. Human osteoclasts in rheumatoid arthritis  
 The ultimate goal of this study is to examine whether an alternative pathway 
induced by TNF and IL-6 is enhanced in RA patients and whether it varies with disease 
activity. Whole human PBMC were used to isolate OCP and OC cultures because it best 
represents the cell population for osteogenesis in physiological conditions. Once the ideal 
conditions for the classic M-CSF/RANKL pathway using with whole PBMC as precursors, 
we will further to test the ability of varying concentrations of TNF/IL-6 to drive 
osteoclastogenesis in vitro. However, our cultures to date have been suboptimal. One 
possible explanation is that we are using frozen PBMC rather than fresh, which could 
hypothetically yield better differentiation. PBMC may have lost differentiation ability 
and/or viability due to the freeze and thaw process after harvest.  
 Once culture conditions are optimized for human OC cultures, the ability of 
TNF/IL-6 OC cultures to resorb bone will be tested by culturing cells on commercially 
available calcium phosphate monolayers for 20 days, followed by von Kossa staining of 
remaining substrate, as previously described15. Resorption area will then be quantified 
using Image J.  As a confirmatory assay, TNF/IL-6 OCs will be cultured on dentin and 
resorption pits visualized with fluorescently labeled wheat germ agglutinin77. In both cases, 
cells will be cultured in parallel with RANKL as a positive control and M-CSF alone as a 
negative control. However, the frequency of OCPs may be too low in total PBMC for 
efficient OC differentiation. In this case, CD14+ peripheral monocytes will be isolated by 
positive selection using CD14 antibody labeled magnetic microbeads (MACS® 
microbeads). Equal density of CD14+ cells will be plated as described above and OC 
 50 
 
formation and resorption activity assayed.  
 In addition to testing fresh PBMC, OCP could be more effectively isolated and 
expanded by using fluorescence activated cell sorting (FACS) to enrich for various myeloid 
precursor populations. In this case, specific populations isolated according to cell surface 
markers would be isolated and cultured for osteoclastogenesis instead of whole PBMC. As 
the next step of the project, cells will be obtained from leukoreduction collars, which are 
used to deplete donated blood for transfusion of all lymphocytes. Subsequently, the cells 
will be stained with panels of monocyte markers and isolated by flow cytometric cell 
sorting using the FACSAria in the Human Immunology Core associated with the 
Rheumatology Division at Brigham and Women’s Hospital. Equal cell numbers from each 
population will be plated in M-CSF with either TNF/IL-6 or RANKL and OC formation 
assessed. Evidence from previous work in the lab and others strongly suggests that human 
OCPs reside in the CD14+ monocyte population29,30 . Thus, PBMC will be gated on CD14+ 
to identify monocytes, and CD14+ cells will be further subdivided into those that are 
cFMS- RANKL-, cFMS+ RANKL+, and cFMS+ RANKL-. The presence of cFMS is 
crucial for osteoclastogenesis as it is the receptor for M-CSF80. The ability of these three 
populations to differentiate into OCs will be compared to total CD14+ cells.  Additional 
markers that can be examined include CX3CR1, which has been reported to identify both 
bone marrow and circulating OCPs in mouse, and CD16, a marker of inflammatory 
monocytes that has been reported to enrich OCPs in psoriatic arthritis 15,64,78. 
 To test whether TNF/IL-6 are sufficient to induce osteoclastogenesis and therefore 
are independent of M-CSF/RANKL pathway, cell cultures with PBMC will be repeated in 
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the presence of OPG, a decoy receptor for RANKL that blocks its activity5. As an 
additional control, blocking antibodies of TNF and IL-6 and/or the Jak inhibitor tofacitinib 
that blocks IL-6 signaling will be used to demonstrate that OC differentiation requires both 
TNF and IL-681.  
4.3. Absence of metabolic stimulation:  Osteoclast-specific Tsc2 deletion in mice 
causes a high bone mass, with clinical implications for bone lesions in Tuberous 
Sclerosis Complex 
4.3.1 Previous studies and experiments 
 While the effect of mTORC1 activity modulation in OC has been examined in some 
detail, little was known about the role of mTORC1 in OC in vivo. In one report, OC 
formation was inhibited by deletion of either mTor or Raptor in hematopoietic precursors 
or ex vivo by rapamycin treatment, suggesting that mTORC1 activity is required for OC 
differentiation67. Consistent with this, rapamycin treatment of aged rats decreased OC 
number and bone resorption as measured by serum TRAP5b68. In contrast, others have 
reported that rapamycin treatment of adult mice increased serum TRAP5b, suggesting that 
rapamycin enhanced OC bone resorption82. 
4.3.2 Tsc2+/- mice as a model for sclerotic bone lesions in Tuberous Sclerosis 
 The skeleton is frequently involved in TSC, with the most common finding being 
sclerotic bone lesions seen in 88-100% of TSC patients45. The sclerotic bone lesions are 
seen most prevalent in vertebral bodies, pedicles and posterior elements, as well as in ribs, 
sternum, proximal femora, and humerus83. Although frequently asymptomatic and poorly 
documented, these lesions can cause back pain and other clinical manifestations84,85. 
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Preliminary observations suggest a worsening of the sclerotic lesions with time81. 
Ossification was also observed within a cortical tuber, thus raising the question if mTORC1 
hyperactivity in specific unknown cells can stimulate ossification through the secretion of 
specific factors, even outside the normal bone tissue87. Little is known about common bone 
diseases in TSC, including whether patients with TSC are more or less likely to develop 
common bone diseases such as osteoporosis and fragility fractures. 
 Despite of the fact that the vast majority of patients with TSC present with dense 
bone lesions, only few mouse models with deficient for TSC1 or TSC2 in bone cells have 
been generated (J.F. Charles, personal communication, November 2016). Generation of 
mouse models with OC-specific Tsc2 deletion would allow further investigation of the role 
of OCs in the development of the bone lesions in TSC. As previously reported, the bone 
lesions in TSC consists of focal areas of dense bone formation, therefore our model 
recapitulates the lesions observed in TSC patients. Tsc2 +/- mice are currently the best 
model to study TSC, since they have the same gene mutation as human patients. It is 
speculated that the dense bone lesions in TSC patients emerge from a second hit mutation 
in OBs and/or in OCs at various stage of development. Reflecting the unknown impact of 
TSC heterozygosity on the skeleton, the Tsc2+/- mouse is a reasonable pre-clinical model 
for skeletal lesions in TSC. This model can be used to assess the histology of these lesions 
and whether they result in bone deformity or focal areas of weakness. TSC2+/- mice can 
also be used to assess how bones respond to long-term administration of rapamycin or 
analogs that are used to treat TSC patients. 
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4.3.3 OC specific loss of Tsc2 causes a high bone mass phenotype 
 In our mouse model, OC-specific Tsc2 deletion led to the increase in trabecular 
bone BV/TV and cortical bone density. The increased resistance to fracture in the mutant 
mice further indicate that the bones formed have good quality. The high bone mass 
phenotype is prominent in almost all parameters in micro-CT imaging analysis and 
develops progressively with age.  The strong, resistant bones in Tsc2ΔOC mice could be 
due to a decrease in OC activity, an increase in OB activity, or the combination of the two. 
Both branches were examined in our study.  
 We find that the loss of Tsc2 does not decrease the generation of OCs, either in 
vitro or in vivo. In fact, the level of OC activity could even be increased, as shown by the 
increase in mRNA expression of Cathepsin K from femurs harvested from 3 month old 
male Tsc2ΔOC mice compared to control. This increase is hard to explain because the 
expression of resorption enzymes and the number of OCs is comparable between Tsc2-
deficient and wild-type OCs. Nevertheless, it further confirms that Tsc2- deficient OCs are 
fully capable of attaining a mature active phenotype. The increase in bone deposition and 
strength, assessed by femur histology, micro-CT scan, and biomechanical testing, was then 
surprising given the unchanged OC number and function in Tsc2ΔOC mice in vitro and in 
vivo.  
 Because of the normal activities of OC, we examined whether alteration in OB 
activity could contribute to the increased bone formation and potentially be the key to 
explaining the high bone mass phenotype. Genetic manipulation of the TSC complex- 
mTORC1 in mice using conditional deletion of Tsc1, Tsc2 or components of mTORC1 has 
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revealed essential functions of these proteins in bone health. A variety of Cre drivers have 
been used to genetically manipulate the TSC complex-mTORC1 pathway at various stages 
of OB differentiation. Since normal bone mineralization requires mTORC1 activity in 
osteoprogenitor cells that give rise to OB, deletion of either mTor or Raptor in these 
precursor cells leads to diminished ossification and short limbs88. However, increased 
mTORC1 activity can be detrimental in more mature OB. Previous studies suggest that OB 
specific deletion of either Tsc1 or Tsc2 results in poor bone quality and impaired 
mineralization, despite of the high bone mass phenotype. The cellular mechanism for the 
poor quality seen with OB-specific Tsc1 or Tsc2 deletion is the reduced maturation of 
mutant OB. Moreover, this phenotype can be rescued by OB-specific deletion of one mTor 
allele or rapamycin treatment, indicating that decrease in OB function is due to an increase 
in mTORC1 activity88,89. 
In contrast to previous findings, our study has found an increased level of OB 
activity due to Tcs2 deletion in Ctsk-expressing cells in mice. P1NP – the bone formation 
marker – was measured in the same plasma samples in which CTX-I was measured. An 
increase in the level of the marker of bone deposition was found in both male and female 
Tsc2ΔOC mice at 3 months and 9 months of age. Interestingly, others have examined the 
serum bone markers by ELISA in a cohort of female patients with TSC (Nico Alesi, M.D., 
February 2017, personal communication). No difference was found in CTX-1 and P1NP 
levels when comparing the patients a control group of age matched females. However, it 
is worth noting that even if almost 100% of the patients have 4 or more bone dense lesions, 
as reported by Avila et al45, the lesions are unlikely to sufficiently increase the circulating 
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P1NP levels to an extent detectable by ELISA. Moreover, both levels of P1NP and CTX-
1 fluctuate enormously throughout one’s life in human. Bone formation markers are 
therefore not the most reliable tool to reflect in vivo OB functions in human.  
 An increase in bone formation marker level in our mouse model confirms that the 
high bone mass phenotype in Tsc2ΔOC mice could be explained by an indirect effect of 
the mutation on OB activity. Two likely explanations include an increase in the number 
and differentiation of OBs and the intrinsic ability of mature OB to form bones. To address 
this, we plan to culture OB lineage cells digested off of the bone surface in vitro and 
examine both OB colony forming units (CFU) and matrix formation. CFU count indicates 
the number of OB precursor cells present in the bone, since OB precursors tend to 
differentiate in clusters of colonies. On the other hand, matrix formation reveals the 
intrinsic bone-forming ability of functional mature OB. A reproducible mouse OB in vitro 
culture protocol has been developed in the lab, along with staining methods that would 
allow for the quantification of both parameters. With the hypothesis that the high bone 
mass phenotype is due to OC-OB interactions, we might expect that OC-specific deletion 
of Tsc2 leads to an increase in differentiation of OB from precursors, rather than the 
functions of mature OB. Therefore, we would expect an increase in CFU in Tsc2ΔOC mice.  
Alternatively, if OC-specific deletion of Tsc2 alters the function of mature OB, there may 
be no difference in CFU assays.  We do not anticipate any cell-intrinsic effects on OB from 
OC-specific deletion of Tsc2, and thus we do not expect a significant difference in matrix 
formation ability between Tsc2ΔOC mice and wild type controls.  
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4.3.4. Stimulation of osteoblast activity by OC-derived CTHRC1 
The increase of OB activity in a mouse model in which Tsc2 is deleted in OCs (or 
other Ctsk-secreting cells) could be explained by alteration of OC-OB coupling. It has been 
suggested that OCs produce soluble or cell surface factors that can stimulate OB function.  
Several of these coupling factors have been identified based on in vitro studies, out of 
which SPHK1, SPHK2 and CTHRC1 were chosen by previous experimenters to be 
examined. In the panel of these factors, there was a huge increase in the expression of 
Cthrc1 mRNA extracted from femurs of 9 months male Tsc2ΔOC mice compared to 
wildtype control, whereas the levels of SPHK1 and SPHK2 did not show significant 
changes (data not shown). Confirming our hypothesis, mRNA extracted from 3 month-old 
Tsc2ΔOC femurs also demonstrated increased Cthrc1 expression in mutants compared to 
controls. Although this increase is more modest compared to the 9 month old difference, it 
is nevertheless significant in a large cohort of animals. The increase in Cthrc1 fold change 
is also in line with the progressive increase in bone mass shown by microCT. 
Although CTHRC1 has been proposed to be secreted by OCs and promote the 
activity of OB62, the exact cell source of this molecule and its mechanism of action are still 
being investigated. A recent article indicates that CTHRC1 is produced by osteocytes – 
cells derived from OBs embedded in bones – to increase bone formation by inhibiting the 
activity of OCs90. Moreover, evidence shows that osteocytes are able to express Cathepsin 
K in female mice during lactation91. Whether the same is true for non-lactating mice is 
unclear. However, if this is the case, then the high bone mass phenotype could be explained 
by Tsc2 deletion in osteocytes and the resultant elevation of osteocyte-derived CTHRC1. 
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To determine the cellular origin of CTHRC1, mice with osteocyte-specific Tsc2 deletion 
could be generated and examined. We would anticipate the presence of high bone mass 
phenotype despite of the unaffected OCs. Radiation chimeras could also be generated, 
since osteocyte precursors are mesenchymal and will not be erased by lethal radiation, 
while OCPs are hematopoietic and will be affected by the procedure.  
4.3.6. Conclusion and future directions 
In conclusion, our study on bone lesions of TSC is the first to establish an in vivo 
mouse model of TSC2 loss in mature OCs. The Tsc2ΔOC mouse model was generated to 
study mTORC1 as a regulator of OC formation and resorptive function. We found instead 
that it could be an indirect regulator of CTHRC1, an OC-OB coupling factor that promotes 
OB activity. Further experiments will be needed to clarify the nature of this regulation. 
Observations from this study have several implications for the advancement of the 
knowledge of TSC as a disease, in which the extraordinary presence of bone lesions has 
just begun to be recognized by the scientific community. Moreover, the recognition of 
mTORC1 as one of the actors involved in the induction of bone formation by OCs may 
suggest potential new avenues of therapy of bone diseases such as osteoporosis. 
 One aim in the future would be to further characterize sclerotic bone lesions 
histologically and identify their microscopic structures. Identifying the cell type that is 
responsible for this clinical manifestation would prompt investigation of human TSC 
patients, whose bone health is not well known. The skeletal impact of Tsc2 heterozygosity 
could be characterized by assessing the mass and strength of these bones with lesions. The 
effects of chronic mTORC1 inhibition on bone mass and strength can also be determined 
 58 
 
with clinically relevant doses of rapamycin in immature and adult mice. Based on our data 
suggesting a role for mTORC1 activity in stimulating OC-derived factor(s) promoting bone 
formation and published data showing a requirement for mTORC1 in OB and OC 
differentiation, we anticipate that long-term treatment with rapamycin will cause adynamic 
bone. These bones may not be different in quantity but will have poorer biomechanical 
properties. In growing animals, where rapid bone formation is needed to attain peak adult 
bone mass, we anticipate a decrease in peak bone mass.  
4.4 Concluding thoughts: environmental inputs are vital for osteoclastogenesis and 
healthy bone  
 Healthy bone is essential for everyday activity and functions in human. Through 
discussions on the role of inflammatory cytokines in the alternative pathways of 
osteoclastogenesis and the effect of metabolic regulators on bone formation, it is evident 
that the bone is a dynamic structure in which key players communicate with one another 
and interact with other systems of the body. The environmental inputs for bone remodeling 
can be regarded as the combination of stimulation via cytokines and the integration of other 
cellular signals. Studies on these stimuli and their regulatory effects on OC and/or OB are 
crucial for understanding disease pathology. New findings such as IL-X as a ligand of CSF-
1R and the presence of alternative osteoclastogenesis pathways in human sparked further 
investigation into the mechanism of OC differentiation and activation, particularly in 
rheumatoid arthritis. The observation of a prominent bone phenotype and bone lesions in 
mutant mice led to the identification of a new animal model for TSC. An increase in 
coupling factors due to mTORC1 hyperactivity in OC offered a new gateway to examine 
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the clinical effect of rapamycin and its analogs in the disease, while also inspired further 
research in other cell types and interactions. Despite of the complexity and intricacy of its 
environmental stimuli, efforts are being made to gain insights of osteoclastogenesis to 
provide effective therapeutics and allow more people to have healthier, stronger bones.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 60 
 
REFERENCES 
1. Charles, J. F. & Aliprantis, A. O. Osteoclasts: more than ‘bone eaters’. Trends in 
Molecular Medicine. 20, 449–459 (2014). 
2. Boyce, B. F. Advances in the Regulation of Osteoclasts and Osteoclast Functions. 
Journal of Dent Research. 0022034513500306 (2013). 
doi:10.1177/0022034513500306 
3. Yokota, K. et al. Combination of tumor necrosis factor α and interleukin-6 induces 
mouse osteoclast-like cells with bone resorption activity both in vitro and in vivo. 
Arthritis Rheumatol. Hoboken NJ 66, 121–129 (2014). 
4. Teitelbaum, S. L. Bone resorption by osteoclasts. Science 289, 1504–1508 (2000). 
5. Kohli, S. S. & Kohli, V. S. Role of RANKL–RANK/osteoprotegerin molecular 
complex in bone remodeling and its immunopathologic implications. Indian Journal 
of Endocrinology and Metabolism. 15, 175–181 (2011). 
6. Ikeda, K. & Takeshita, S. Factors and Mechanisms Involved in the Coupling from 
Bone Resorption to Formation: How Osteoclasts Talk to Osteoblasts. Journal of Bone 
Metabolism. 21, 163 (2014). 
7. Boyle, W. J., Simonet, W. S. & Lacey, D. L. Osteoclast differentiation and activation. 
Nature 423, 337–342 (2003). 
8. Franz-Odendaal, T. A., Hall, B. K. & Witten, P. E. Buried alive: How osteoblasts 
become osteocytes. Developmental Dynamics. 235, 176–190 (2006). 
 61 
 
9. Boström, E. A. & Lundberg, P. The Newly Discovered Cytokine IL-34 Is Expressed 
in Gingival Fibroblasts, Shows Enhanced Expression by Pro-Inflammatory 
Cytokines, and Stimulates Osteoclast Differentiation. PLOS ONE 8, e81665 (2013). 
10. Stanley, E. R. & Chitu, V. CSF-1 Receptor Signaling in Myeloid Cells. Cold Spring 
Harbor Perspectives in Biology. 6, a021857 (2014). 
11. Hwang, S.-J. et al. Interleukin-34 produced by human fibroblast-like synovial cells in 
rheumatoid arthritis supports osteoclastogenesis. Arthritis Research & Therapy. 14, 
R14 (2012). 
12. Nandi, S. et al. Receptor-type Protein-tyrosine Phosphatase ζ Is a Functional 
Receptor for Interleukin-34. The Journal of Biological Chemistry. 288, 21972–21986 
(2013). 
13. Dai, X.-M. et al. Targeted disruption of the mouse colony-stimulating factor 1 
receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased 
primitive progenitor cell frequencies, and reproductive defects. Blood 99, 111–120 
(2002). 
14. Begg, S. K. et al. Delayed hematopoietic development in osteopetrotic (op/op) mice. 
The Journal of Experimental Medicine. 177, 237–242 (1993). 
15. Charles, J. F. et al. Inflammatory arthritis increases mouse osteoclast precursors with 
myeloid suppressor function. Journal of Clinical Investigation. 122, 4592–4605 
(2012). 
 62 
 
16. Baud’Huin, M. et al. Interleukin-34 is expressed by giant cell tumours of bone and 
plays a key role in RANKL-induced osteoclastogenesis. The Journal of Pathology. 
221, 77–86 (2010). 
17. Chen, Z., Buki, K., Vääräniemi, J., Gu, G. & Väänänen, H. K. The Critical Role of 
IL-34 in Osteoclastogenesis. PLOS ONE 6, e18689 (2011). 
18. Christensen, A. D., Haase, C., Cook, A. D. & Hamilton, J. A. K/BxN Serum-Transfer 
Arthritis as a Model for Human Inflammatory Arthritis. Frontiers in Immunology. 7, 
(2016). 
19. Kouskoff, V. et al. Organ-specific disease provoked by systemic autoimmunity. Cell 
87, 811–822 (1996). 
20. Holling, T. M., Schooten, E. & van Den Elsen, P. J. Function and regulation of MHC 
class II molecules in T-lymphocytes: of mice and men. Human Immunology. 65, 
282–290 (2004). 
21. Ditzel, H. J. The K/BxN mouse: a model of human inflammatory arthritis. Trends in 
Molecular Medicine. 10, 40–45 (2004). 
22. Matsumoto, I., Staub, A., Benoist, C. & Mathis, D. Arthritis provoked by linked T 
and B cell recognition of a glycolytic enzyme. Science 286, 1732–1735 (1999). 
23. Monach, P. et al. The K/BxN mouse model of inflammatory arthritis: theory and 
practice. Methods in Molecular Medicine. 136, 269–282 (2007). 
24. Ji, H. et al. Genetic Influences on the End-Stage Effector Phase of Arthritis. The 
Journal of Experimental Medicine. 194, 321–330 (2001). 
 63 
 
25. Böttcher, J. & Pfeil, A. Diagnosis of periarticular osteoporosis in rheumatoid arthritis 
using digital X-ray radiogrammetry. Arthritis Research & Therapy. 10, 103 (2008). 
26. Myasoedova, E., Crowson, C. S., Kremers, H. M., Therneau, T. M. & Gabriel, S. E. 
Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, 
Minnesota, 1955-2007. Arthritis Rheumatology. 62, 1576–1582 (2010). 
27. Athanasou, N. A. Current Concepts Review - Cellular Biology of Bone-Resorbing 
Cells*. The Journal of Bone and Joint Surgery. American Volume. 78, 1096–1112 
(1996). 
28. Adamopoulos, I. E. & Mellins, E. D. Alternative pathways of osteoclastogenesis in 
inflammatory arthritis. Nature Reviews Rheumatology. 11, 189–194 (2014). 
29. Li, P. et al. RANK signaling is not required for TNFalpha-mediated increase in 
CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in 
TNFalpha-mediated inflammatory arthritis. Journal of Bone and Mineral Research: 
the Official Journal of the American Society for Bone and Mineral Research. 19, 
207–213 (2004). 
30. Locksley, R. M., Killeen, N. & Lenardo, M. J. The TNF and TNF receptor 
superfamilies: integrating mammalian biology. Cell 104, 487–501 (2001). 
31. Jaffer, U., Wade, R. G. & Gourlay, T. Cytokines in the systemic inflammatory 
response syndrome: a review. HSR Proceedings in Intensive Care and 
Cardiovascular Anesthesia. 2, 161–175 (2010). 
 64 
 
32. Mokart, D. et al. Early postoperative compensatory anti-inflammatory response 
syndrome is associated with septic complications after major surgical trauma in 
patients with cancer. British Journal of Surgery. 89, 1450–1456 (2002). 
33. Swardfager, W. et al. A meta-analysis of cytokines in Alzheimer’s disease. 
Biological Psychiatry 68, 930–941 (2010). 
34. Dowlati, Y. et al. A meta-analysis of cytokines in major depression. Biological 
Psychiatry 67, 446–457 (2010). 
35. Victor, F. C. & Gottlieb, A. B. TNF-alpha and apoptosis: implications for the 
pathogenesis and treatment of psoriasis. Journal of Drugs in Dermatology. JDD 1, 
264–275 (2002). 
36. Weitzmann, M. N. & Weitzmann, M. N. The Role of Inflammatory Cytokines, the 
RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone 
Turnover and Osteoporosis, The Role of Inflammatory Cytokines, the RANKL/OPG 
Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and 
Osteoporosis. Science. 2013, 2013, e125705 (2013). 
37. Banks, W. A., Kastin, A. J. & Gutierrez, E. G. Penetration of interleukin-6 across the 
murine blood-brain barrier. Neuroscience Letters. 179, 53–56 (1994). 
38. van der Poll, T. et al. Interleukin-6 gene-deficient mice show impaired defense 
against pneumococcal pneumonia. The Journal of Infectious Diseases. 176, 439–444 
(1997). 
 65 
 
39. Tamura, T. et al. Soluble interleukin-6 receptor triggers osteoclast formation by 
interleukin 6. Proceedings of the National Academy of Sciences. U. S. A. 90, 11924–
11928 (1993). 
40. O’Brien, W. et al. RANK-Independent Osteoclast Formation and Bone Erosion in 
Inflammatory Arthritis. Arthritis Rheumatol. 68, 2889–2900 (2016). 
41. Staley, B. A., Vail, E. A. & Thiele, E. A. Tuberous Sclerosis Complex: Diagnostic 
Challenges, Presenting Symptoms, and Commonly Missed Signs. Pediatrics 127, 
e117–e125 (2011). 
42. Holmes, G. L., Stafstrom, C. E. & Tuberous Sclerosis Study Group. Tuberous 
sclerosis complex and epilepsy: recent developments and future challenges. Epilepsia 
48, 617–630 (2007). 
43. Cudzilo, C. J. et al. Lymphangioleiomyomatosis screening in women with tuberous 
sclerosis. Chest 144, 578–585 (2013). 
44. D, H. A. Imaging of tuberous sclerosis lesions outside of the central nervous system. 
Johnson, W G And M R Gomez (Ed ) Annals Of The New York Academy Of Sciences, 
Vol 615 Tuberous Sclerosis And Allied Disorders (1991). Available at: 
https://eurekamag.com/research/031/801/031801548.php. (Accessed: 15th February 
2017) 
45. Avila, N. A. et al. CT of Sclerotic Bone Lesions: Imaging Features Differentiating 
Tuberous Sclerosis Complex with Lymphangioleiomyomatosis from Sporadic 
Lymphangioleiomymatosis1. Radiology 254, 851–857 (2010). 
 66 
 
46. Dimsdale, H. Tuberose Sclerosis with Intracranial Calcification and Lesions of Bone. 
Proceedings of the Royal Society of Medicine. 40, 81–82 (1946). 
47. Janssen, B. et al. Refined localization of TSC1 by combined analysis of 9q34 and 
16p13 data in 14 tuberous sclerosis families. Human Genetics. 94, 437–440 (1994). 
48. Povey, S. et al. Two loci for tuberous sclerosis: one on 9q34 and one on 16p13. Ann. 
Human Genetics. 58, 107–127 (1994). 
49. Sepp, T., Yates, J. R. & Green, A. J. Loss of heterozygosity in tuberous sclerosis 
hamartomas. Journal of Medical Genetics. 33, 962–964 (1996). 
50. Vézina, C., Kudelski, A. & Sehgal, S. N. Rapamycin (AY-22,989), a new antifungal 
antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active 
principle. The Journal of Antibiotics. (Tokyo) 28, 721–726 (1975). 
51. Koltin, Y. et al. Rapamycin sensitivity in Saccharomyces cerevisiae is mediated by a 
peptidyl-prolyl cis-trans isomerase related to human FK506-binding protein. 
Molecular and Cellular Biology. 11, 1718–1723 (1991). 
52. Loewith, R. et al. Two TOR complexes, only one of which is rapamycin sensitive, 
have distinct roles in cell growth control. Molecular Cell 10, 457–468 (2002). 
53. Cejka, D. et al. Mammalian target of rapamycin signaling is crucial for joint 
destruction in experimental arthritis and is activated in osteoclasts from patients with 
rheumatoid arthritis. Arthritis & Rheumatology. 62, 2294–2302 (2010). 
54. Jaeschke, A. et al. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase 
inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. The Journal 
of Cell Biology. 159, 217–224 (2002). 
 67 
 
55. Price, D. J., Grove, J. R., Calvo, V., Avruch, J. & Bierer, B. E. Rapamycin-induced 
inhibition of the 70-kilodalton S6 protein kinase. Science 257, 973–977 (1992). 
56. Manning, B. D. & Cantley, L. C. Rheb fills a GAP between TSC and TOR. Trends in 
Biochemical Sciences. 28, 573–576 (2003). 
57. Tee, A. R., Manning, B. D., Roux, P. P., Cantley, L. C. & Blenis, J. Tuberous 
sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by 
acting as a GTPase-activating protein complex toward Rheb. Current Biology. CB 13, 
1259–1268 (2003). 
58. Dibble, C. C. & Manning, B. D. Signal integration by mTORC1 coordinates nutrient 
input with biosynthetic output. Nature Cell Biology. 15, 555–564 (2013). 
59. Sancak, Y. et al. The Rag GTPases bind raptor and mediate amino acid signaling to 
mTORC1. Science 320, 1496–1501 (2008). 
60. Oshiro, N. et al. Dissociation of raptor from mTOR is a mechanism of rapamycin-
induced inhibition of mTOR function. Genes to Cells: Devoted to Molecular & 
Cellular Mechanisms. 9, 359–366 (2004). 
61. Takeshita, S. et al. Osteoclast-secreted CTHRC1 in the coupling of bone resorption 
to formation. Journal of Clinical Investigation. 123, 3914–3924 (2013). 
62. Matsuoka, K., Park, K.-A., Ito, M., Ikeda, K. & Takeshita, S. Osteoclast-derived 
complement component 3a stimulates osteoblast differentiation. Journal of Bone and 
Mineral Research: the Official Journal of the American Society for Bone and Mineral 
Research. 29, 1522–1530 (2014). 
 68 
 
63. Ishii, M. et al. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates 
bone homeostasis. Nature 458, 524–528 (2009). 
64. Office of the Surgeon General (US). Bone Health and Osteoporosis: A Report of the 
Surgeon General. (Office of the Surgeon General (US), 2004). 
65. Cosman, F. et al. Clinician’s Guide to Prevention and Treatment of Osteoporosis. 
Osteoporos. Int. J. Establ. Result Coop. Eur. Found. Osteoporos. Natl. Osteoporos. 
Found. 25, 2359–2381 (2014). 
66. Indo, Y. et al. Metabolic regulation of osteoclast differentiation and function. Journal 
of Bone and Mineral Research: the Official Journal of the American Society for Bone 
and Mineral Research. 28, 2392–2399 (2013). 
67. Luo, D., Ren, H., Li, T., Lian, K. & Lin, D. Rapamycin reduces severity of senile 
osteoporosis by activating osteocyte autophagy. Osteoporos. Int. J. Establ. Result 
Coop. Eur. Found. Osteoporos. Natl. Osteoporos. Found. USA 27, 1093–1101 
(2016). 
68. Hayman, A. R. Tartrate-resistant acid phosphatase (TRAP) and the 
osteoclast/immune cell dichotomy. Autoimmunity 41, 218–223 (2008). 
69. Alatalo, S. L., Halleen, J. M., Hentunen, T. A., Mönkkönen, J. & Väänänen, H. K. 
Rapid screening method for osteoclast differentiation in vitro that measures tartrate-
resistant acid phosphatase 5b activity secreted into the culture medium. Clinical 
Chemistry. 46, 1751–1754 (2000). 
70. Zhang, J. et al. Conditional gene manipulation: Cre-ating a new biological era. 
Journal of Zhejiang University- Science B. 13, 511–524 (2012). 
 69 
 
71. Winkeler, C. L., Kladney, R. D., Jr, L. B. M. & Weber, J. D. Cathepsin K-Cre Causes 
Unexpected Germline Deletion of Genes in Mice. PLOS ONE 7, e42005 (2012). 
72. Hernandez, O., Way, S., McKenna, J. & Gambello, M. J. Generation of a conditional 
disruption of the Tsc2 gene. Genes. N. Y. N 2000 45, 101–106 (2007). 
73. Onda, H., Lueck, A., Marks, P. W., Warren, H. B. & Kwiatkowski, D. J. Tsc2+/– 
mice develop tumors in multiple sites that express gelsolin and are influenced by 
genetic background. Journal of Clinical Investigation. 104, 687–695 (1999). 
74. Osteo Assay | Osteo Assay Surface | Corning. Available at: 
https://www.corning.com/worldwide/en/products/life-
sciences/products/surfaces/osteo-assay.html. (Accessed: 24th February 2017) 
75. Bone Markers in Osteoporosis: Bone Turnover Markers, Bone Formation Markers, 
Bone Resorption Markers. (2017). 
76. Charles, J. F. et al. The collection of NFATc1-dependent transcripts in the osteoclast 
includes numerous genes non-essential to physiologic bone resorption. Bone 51, 902–
912 (2012). 
77. Chiu, Y. G. et al. CD16 (FcRgammaIII) as a potential marker of osteoclast precursors 
in psoriatic arthritis. Arthritis Research & Therapy. 12, R14 (2010). 
78. Nicholson, G. C. et al. Induction of osteoclasts from CD14-positive human peripheral 
blood mononuclear cells by receptor activator of nuclear factor kappaB ligand 
(RANKL). Clinical Science. (London England: 1979) 99, 133–140 (2000). 
79. Ross, F. P. M-CSF, c-Fms, and signaling in osteoclasts and their precursors. Annals 
of the New York Academy of Sciences. 1068, 110–116 (2006). 
 70 
 
80. Hodge, J. A. et al. The mechanism of action of tofacitinib - an oral Janus kinase 
inhibitor for the treatment of rheumatoid arthritis. Clinical and Experimental 
Rheumatology. 34, 318–328 (2016). 
81. Niziolek, P. J. et al. Rapamycin impairs trabecular bone acquisition from high-dose 
but not low-dose intermittent parathyroid hormone treatment. Journal of Cellular 
Physiology. 221, 579–585 (2009). 
82. MX1 MX dynamin like GTPase 1 [Homo sapiens (human)] - Gene - NCBI. 
Available at: https://www.ncbi.nlm.nih.gov/gene/4599. (Accessed: 4th March 2017) 
83. Boronat, S., Barber, I., Pargaonkar, V., Chang, J. & Thiele, E. A. Sclerotic bone 
lesions at abdominal magnetic resonance imaging in children with tuberous sclerosis 
complex. Pediatrics Radiology. 46, 689–694 (2016). 
84. Stosic-Opincal, T. et al. Spine MRI findings in a patient with tuberous sclerosis: a 
case report--part II. Spine 30, 992–993 (2005). 
85. Tashiro, M. et al. Pancytopenia in tuberous sclerosis. Medical Science Monitor: 
International Medical Journal of Experimental and Clinical Research. 7, 444–447 
(2001). 
86. Li, P. et al. Rib and vertebral bone fibrous dysplasia in a child with tuberous sclerosis 
complex. American Journal of Medical Genetics Part A. 167A, 2755–2757 (2015). 
87. Breningstall, G. N., Faerber, E. N. & Kolanu, R. Fibrous dysplasia in a patient with 
tuberous sclerosis. Journal of Child Neurology. 3, 131–134 (1988). 
88. Martin, S. K. et al. NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, 
promotes osteogenic differentiation in human mesenchymal stromal cells. Journal of 
 71 
 
Bone and Mineral Research: the Official Journal of the American Society for Bone 
and Mineral Research. 25, 2126–2137 (2010). 
89. Riddle, R. C. et al. Tsc2 is a molecular checkpoint controlling osteoblast 
development and glucose homeostasis. Molecular and Cellular Biology. 34, 1850–
1862 (2014). 
90. Jin, Y.-R. et al. Inhibition of osteoclast differentiation and collagen antibody-induced 
arthritis by CTHRC1. Bone 97, 153–167 (2017). 
91. Qing, H. et al. Demonstration of osteocytic perilacunar/canalicular remodeling in 
mice during lactation. Journal of Bone and Mineral Research: the Official Journal of 
the American Society for Bone and Mineral Research. 27, 1018–1029 (2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 72 
 
CURRICULUM VITAE 
 73 
 
 74 
 
        
 75 
 
